Source: https://patents.google.com/patent/AU728051B2/en
Timestamp: 2019-07-17 05:39:47
Document Index: 229416168

Matched Legal Cases: ['Art 19', 'arts 22', 'Application No. 0', 'Application No.\n2', 'Application No. 0', 'art, 3', 'Application No. 0']

AU728051B2 - Aryl or heteroaryl substituted 3,4-dihydroanthracene and aryl or heteroaryl substituted benzo{1,2-g}-chrom-3-ene, benzo{1,2-g}-thiochrom-3-ene and benzo{1,2-g}-1,2-dihydroquinoline derivatives having retinoid antagonist or retinoid inverse agonist type biological activity - Google Patents
Aryl or heteroaryl substituted 3,4-dihydroanthracene and aryl or heteroaryl substituted benzo{1,2-g}-chrom-3-ene, benzo{1,2-g}-thiochrom-3-ene and benzo{1,2-g}-1,2-dihydroquinoline derivatives having retinoid antagonist or retinoid inverse agonist type biological activity Download PDF
AU728051B2
AU728051B2 AU56929/98A AU5692998A AU728051B2 AU 728051 B2 AU728051 B2 AU 728051B2 AU 56929/98 A AU56929/98 A AU 56929/98A AU 5692998 A AU5692998 A AU 5692998A AU 728051 B2 AU728051 B2 AU 728051B2
AU56929/98A
AU5692998A (en
1996-12-12 Priority to US08/764466 priority Critical
1996-12-12 Priority to US08/764,466 priority patent/US5728846A/en
1997-12-09 Application filed by Allergan Sales LLC filed Critical Allergan Sales LLC
1997-12-09 Priority to PCT/US1997/022581 priority patent/WO1998025875A1/en
1998-07-03 Publication of AU5692998A publication Critical patent/AU5692998A/en
2001-01-04 Publication of AU728051B2 publication Critical patent/AU728051B2/en
2002-05-22 First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25070815&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU728051(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
2003-10-09 Assigned to ALLERGAN, INC. reassignment ALLERGAN, INC. Alteration of Name(s) in Register under S187 Assignors: ALLERGAN SALES, INC.
WO 98/25875 PCT/US97/22581 1 1 ARYL OR HETEROARYL SUBSTITUTED 3,4- 2 DIHYDROANTHRACENE AND ARYL OR HETEROARYL 3 SUBSTITUTED BENZO[1,2-g]-CHROM-3-ENE, BENZO[1,2-g]- 4 THIOCHROM-3-ENE AND BENZO[1,2-g]-1,2-DIHYDROQUINOLINE DERIVATIVES HAVING RETINOID ANTAGONIST OR RETINOID 6 INVERSE AGONIST 7 TYPE BIOLOGICAL ACTIVITY 8 BACKGROUND OF THE INVENTION 9 1. Field of the Invention The present invention relates to novel compounds having 11 retinoid-like, retinoid antagonist and/or retinoid inverse-agonist-like 12 biological activity. More specifically, the present invention relates to 13 aryl or heteroaryl substituted 3,4-dihydroanthracene and aryl or 14 heteroaryl substituted benzo[1,2-g]-chrom-3-ene, benzo[1,2-g]thiochrom-3-ene and benzo[1,2-g]-1,2-dihydroquinoline derivatives 16 which bind to retinoid receptors and have retinoid-like, retinoid 17 antagonist or retinoid inverse agonist-like biological activity.
18 2. Background Art 19 Compounds which have retinoid-like activity are well known in the art, and are described in numerous United States and 21 other patents and in scientific publications. It is generally known and 22 accepted in the art that retinoid-like activity is useful for treating 23 animals of the mammalian species, including humans, for curing or 24 alleviating the symptoms and conditions of numerous diseases and conditions. In other words, it is generally accepted in the art that 26 pharmaceutical compositions having a retinoid-like compound or 27 compounds as the active ingredient are useful as regulators of cell 28 proliferation and differentiation, and particularly as agents for treating 29 skin-related diseases, including, actinic keratoses, arsenic keratoses, inflammatory and non-inflammatory acne, psoriasis, ichthyoses and WO 98/25875 PCT/US97/22581 2 1 other keratinization and hyperproliferative disorders of the skin, 2 eczema, atopic dermatitis, Darriers disease, lichen planus, prevention 3 and reversal of glucocorticoid damage (steroid atrophy), as a topical 4 anti-microbial, as skin anti-pigmentation agents and to treat and reverse the effects of age and photo damage to the skin. Retinoid compounds 6 are also useful for the prevention and treatment of cancerous and 7 precancerous conditions, including, premalignant and malignant 8 hyperproliferative diseases such as cancers of the breast, skin, prostate, 9 cervix, uterus, colon, bladder, esophagus, stomach, lung, larynx, oral cavity, blood and lymphatic system, metaplasias, dysplasias, neoplasias, 11 leukoplakias and papillomas of the mucous membranes and in the 12 treatment of Kaposi's sarcoma. In addition, retinoid compounds can be 13 used as agents to treat diseases of the eye, including, without limitation, 14 proliferative vitreoretinopathy (PVR), retinal detachment, dry eye and other corneopathies, as well as in the treatment and prevention of 16 various cardiovascular diseases, including, without limitation, diseases 17 associated with lipid metabolism such as dyslipidemias, prevention of 18 post-angioplasty restenosis and as an agent to increase the level of 19 circulating tissue plasminogen activator (TPA). Other uses for retinoid compounds include the prevention and treatment of conditions and 21 diseases associated with human papilloma virus (HPV), including warts 22 and genital warts, various inflammatory diseases such as pulmonary 23 fibrosis, ileitis, colitis and Krohn's disease, neurodegenerative diseases 24 such as Alzheimer's disease, Parkinson's disease and stroke, improper pituitary function, including insufficient production of growth hormone, 26 modulation of apoptosis, including both the induction of apoptosis and 27 inhibition of T-Cell activated apoptosis, restoration of hair growth, 28 including combination therapies with the present compounds and other 29 agents such as MinoxidilR, diseases associated with the immune system, including use of the present compounds as immunosuppressants and WO 98/25875 PCT/US97/22581 3 1 immunostimulants, modulation of organ transplant rejection and 2 facilitation of wound healing, including modulation of chelosis.
3 European Patent Application No. 0 210 929 (published on 4 February 4, 1987) describes polycyclic compounds which are said to s have certain retinoid-like, or related biological activity. United States 6 Patent Nos. 4,980,369, 5,006,550, 5,015,658, 5,045,551, 5,089,509, 7 5,134,159, 5,162,546, 5,234,926, 5,248,777, 5,264,578, 5,272,156, a 5,278,318, 5,324,744, 5,346,895, 5,346,915, 5,348,972, 5,348,975, 9 5,380,877, 5,399,561 and 5,407,937, (assigned to the same assignee as the present application) and patents and publications cited therein, describe 11 or relate to chroman, thiochroman and 1,2,3,4-tetrahydroquinoline 12 derivatives which have retinoid-like biological activity.
13 United States Patent Nos. 5,130,335; 5,324,840; 5,344,959; 14 5,451,605; 5,455,265; 5,470,999; 5,475,022; 5,475,113; 5,489,584; 1i 5,514,825; 5,543,534; (assigned to the same assignee as the present 16 application) and patents and publications cited therein, describe or 17 relate to 5, 6 ,7,8-tetrahydronaphthalene or naphthalene derivatives which 18 have retinoid-like biological activity.
19 Still further, several co-pending applications and recently issued patents which are assigned to the assignee of the present application, 21 are directed to further compounds having retinoid-like activity.
22 Although pharmaceutical compositions containing retinoids have 23 well established utility (as is demonstrated by the foregoing citation of 24 patents and publications from the voluminous literature devoted to this subject) retinoids also cause a number of undesired side effects at 26 therapeutic dose levels, including headache, teratogenesis, 27 mucocutaneous toxicity, musculoskeletal toxicity, dyslipidemias, skin 28 irritation, headache and hepatotoxicity. These side effects limit the 29 acceptability and utility of retinoids for treating disease.
It is now general knowledge in the art that two main types of WO 98/25875 PCTIUS97/22581 4 1 retinoid receptors exist in mammals (and other organisms). The two 2 main types or families of receptors are respectively designated the 3 RARs and RXRs. Within each type there are subtypes; in the RAR 4 family the subtypes are designated RAR., RAR, and RARy, in RXR the subtypes are: RXR,, RXB3 and RXRy. It has also been established 6 in the art that the distribution of the two main retinoid receptor types, 7 and of the several sub-types is not uniform in the various tissues and 8 organs of mammalian organisms. Moreover, it is generally accepted in 9 the art that many unwanted side effects of retinoids are mediated by one or more of the RAR receptor subtypes. Accordingly, among 11 compounds having agonist-like activity at retinoid receptors, specificity 12 or selectivity for one of the main types or families, and even specificity 13 or selectivity for one or more subtypes within a family of receptors, is 14 considered a desirable pharmacological property, Some compounds bind to one or more RAR receptor subtypes, but do not trigger the 16 response which is triggered by agonists of the same receptors. A 17 compound that binds to a biological receptor but does not trigger an 18 agonist-like response is usually termed an antagonist. Accordingly, the 19 "effect" of compounds on retinoid receptors may fall in the range of having no effect at all, (inactive compound, neither agonist nor 21 antagonist), the compound may elicit an agonist-like response on all 22 receptor subtypes (pan-agonist), or a compound may be a partial agonist 23 and/or partial antagonist of certain receptor subtypes if the compound 24 binds to but does not activate certain receptor subtype or subtypes but elicits an agonist-like response in other receptor subtype or subtypes.
26 A pan antagonist is a compound that binds to all known retinoid 27 receptors but does not elicit an agonist-like response in any of the 28 receptors.
29 Recently a two-state model for certain receptors, including the above-mentioned retinoid receptors, have emerged. In this model, an WO 98/25875 PCT/US97/22581 1 equilibrium is postulated to exist between inactive receptors and 2 spontaneously active receptors which are capable of coupling with a G 3 protein in the absence of a ligand (agonist). In this model, so-called 4 "inverse agonists" shift the equilibrium toward inactive receptors, thus bringing about an overall inhibitory effect. Neutral antagonist do not 6 effect the receptor equilibrium but are capable of competing for the 7 receptors with both agonists (ligands) and with inverse agonists.
8 It has been recently discovered and described in pending 9 applications assigned to the same assignee as the present application that the above mentioned retinoid antagonist and/or inverse agonist- 11 like activity of a compound is also a useful property, in that such 12 antagonist or inverse agonist-like compounds can be utilized to block 13 certain undesired side effects of retinoids, to serve as antidotes to 14 retinoid overdose or poisoning, and may lend themselves to other pharmaceutical applications as well. More particularly, regarding the 16 published scientific and patent literature in this field, published PCT 17 application WO 94/14777 describes certain heterocyclic carboxylic acid 8i derivatives which bind to RAR retinoid receptors and are said in the 19 application to be useful for treatment of certain diseases or conditions, such as acne, psoriasis, rheumatoid arthritis and viral infections. A 21 similar disclosure is made in the article by Yoshimura et al. J Med.
22 Chem. 1995, 38, 3163-3173. Kaneko et al. Med. Chem Res. (1991) 23 1:220-225; Apfel et al. Proc. Natl. Acad. Sci. USA Vol 89 pp 7129-7133 24 August 1992 Cell Biology; Eckhardt et al. Toxicology Letters, 70 (1994) 299-308; Keidel et al. Molecular and Cellular Biology, Vol 14, No. 1, 26 Jan. 1994, p 287-298; and Evrolles et al. J. Med. Chem. 1994, 37, 27 1508-1517 describe compounds which have antagonist like activity at one 28 or more of the RAR retinoid subtypes.
29 SUMMARY OF THE INVENTION The present invention relates to compounds of Formula 1 R (R 4 n R2) X Il Y(R2n-A-B Formula 1 wherein X, is -C(R 1 2 -C(Rx) 2
-C(R)
2 -C(Rx) 2 0-, or-C(R,-NR,-;
1 is independently H or alkyl of 1 to 6 carbons or cycloalkyl of 3 to 6 carbons;
2 is optional and is defined as lower alkyl of 1 to 6 carbons or cycloalkyl of 3 to 6 carbons, F, Cl, Br, I, CF 3 fluoro substituted alkyl of 1 to 6 carbons or fluoro substituted cycloalkyl of 3 to 6 carbons, OH, SH, alkoxy of 1 to 6 carbons, or alkylthio of 1 to 6 carbons; m is an integer between 0 and 4; n n is an integer between 0 and 2; o is an integer between 0 and 3;
3 is hydrogen, lower alkyl of 1 to 6 carbons or cycloalalkyl of 3 to 6 carbons, F, Cl, Br, or I;
4 is (Rs)p-phenyl, (Rs)p-naphthyl, or (Rs)p-heteroaryl where the heteroaryl group is 5-membered of 6-membered and has 1 to 3 heteroatoms selected from the Sgroup consisting of O, S, and N; p is an integer having the values of 0 Rs is optional and is defined as independently F, Cl, Br, I, NO 2 N(Rs) 2 N(Rs)CORs, NRsCON(R) 2 OH, OCOR8, OR, CN, COOH, COOR an alkyl group having 1 to 10 carbons or cycloalkyl of 3 to 10 carbons, fluoro substituted alkyl group having 1 to 10 carbons or fluoro substituted cycloalkyl of 3 to carbons, an alkenyl group having 2 to 10 carbons and 1 to 3 double bonds or a cycloalkenyl group having 3 to 10 carbons and 1 to 3 double bonds, alkenyl group having 2 to 10 carbons and 1 to 3 triple bonds, or a (trialkyl)silyl or S(trialkyl)silyloxy group where the alkyl groups independently have 1 to 6 carbons or cycloalkyl of 3 to 6 carbons; 6A Y is a phenyl or naphthyl group, or heteroaryl selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, p.
9 9 WO 98/25875 PCT/US97/22581 7 1 pyrazinyl, thiazolyl, oxazolyl, imidazolyl and pyrrazolyl, said phenyl and 2 heteroaryl groups being optionally substituted with one or two R 2 3 groups, or Y is -(CR 3
3 4 r is an integer between 1 and 3; A is (CH 2 )q where q is 0-5, lower branched chain alkyl 6 having 3-6 carbons, cycloalkyl having 3-6 carbons, alkenyl having 2-6 7 carbons and 1 or 2 double bonds, alkynyl having 2-6 carbons and 1 or 2 8 triple bonds, with the proviso that when Y is 9 -(CR 3
3 then A is (CH 2 )q and q is 0; B is hydrogen, COOH or a pharmaceutically acceptable salt 11 thereof, COOR 8 CONRRio, -CH 2 OH, CH 2 OR, CH 2
12 CH(ORU) 2
1 3 O, -COR 7
CR,(OR,)
1 3 O, or Si(Ci.
6 alkyl) 3 13 where R 7 is an alkyl, cycloalkyl or alkenyl group containing 1 to 14 carbons, R, is an alkyl group of 1 to 10 carbons or (trimethylsilyl)alkyl 1i where the alkyl group has 1 to 10 carbons, or a cycloalkyl group of 5 to 16 10 carbons, or R 8 is phenyl or lower alkylphenyl, R 9 and R 0 i 17 independently are hydrogen, an alkyl group of 1 to 10 carbons, or a is cycloalkyl group of 5-10 carbons, or phenyl or lower alkylphenyl, is 19 lower alkyl, phenyl or lower alkylphenyl, R2 is lower alkyl, and R 13 is divalent alkyl radical of 2-5 carbons.
21 In a second aspect, this invention relates to the use of the 22 compounds of Formula 1 for the treatment of skin-related diseases, 23 including, without limitation, actinic keratoses, arsenic keratoses, 24 inflammatory and non-inflammatory acne, psoriasis, ichthyoses and other keratinization and hyperproliferative disorders of the skin, 26 eczema, atopic dermatitis, Darriers disease, lichen planus, prevention 27 and reversal of glucocorticoid damage (steroid atrophy), as a topical 28 anti-microbial, as skin anti-pigmentation agents and to treat and reverse 29 the effects of age and photo damage to the skin. The compounds are also useful for the prevention and treatment of cancerous and WO 98/25875 PCT/US97/22581 8 1 precancerous conditions, including, premalignant and malignant 2 hyperproliferative diseases such as cancers of the breast, skin, prostate, 3 cervix, uterus, colon, bladder, esophagus, stomach, lung, larynx, oral 4 cavity, blood and lymphatic system, metaplasias, dysplasias, neoplasias, s leukoplakias and papillomas of the mucous membranes and in the 6 treatment of Kaposi's sarcoma. In addition, the present compounds can 7 be used as agents to treat diseases of the eye, including, without 8 limitation, proliferative vitreoretinopathy (PVR), retinal detachment, dry 9 eye and other corneopathies, as well as in the treatment and prevention of various cardiovascular diseases, including, without limitation, diseases 11 associated with lipid metabolism such as dyslipidemias, prevention of 12 post-angioplasty restenosis and as an agent to increase the level of 13 circulating tissue plasminogen activator (TPA). Other uses for the 14 compounds of the present invention include the prevention and treatment of conditions and diseases associated with Human papilloma 16 virus (HPV), including warts and genital warts, various inflammatory 17 diseases such as pulmonary fibrosis, ileitis, colitis and Krohn's disease, 18 neurodegenerative diseases such as Alzheimer's disease, Parkinson's 19 disease and stroke, improper pituitary function, including insufficient production of growth hormone, modulation of apoptosis, including both 21 the induction of apoptosis and inhibition of T-Cell activated apoptosis, 22 restoration of hair growth, including combination therapies with the 23 present compounds and other agents such as MinoxidilR, diseases 24 associated with the immune system, including use of the present compounds as immunosuppressants and immunostimulants, modulation 26 of organ transplant rejection and facilitation of wound healing, including 27 modulation of chelosis.
28 Alternatively, those compounds of the invention which act as 29 antagonists or inverse agonists of one or more retinoid receptor subtypes are useful to prevent certain undesired side effects of retinoids WO 98/25875 PCT/US97/22581 9 1 which are administered for the treatment or prevention of certain 2 diseases or conditions. For this purpose the retinoid antagonist and/or 3 inverse agonist compounds of the invention may be co-administered 4 with retinoids. The retinoid antagonist and inverse agonist compounds of the present invention are also useful in the treatment of acute or 6 chronic toxicity resulting from overdose or poisoning by retinoid drugs 7 or Vitamin A.
8 This invention also relates to a pharmaceutical formulation 9 comprising a compound of Formula 1 in admixture with a pharmaceutically acceptable excipient, said formulation being adapted 11 for administration to a mammal including a human being, to treat or 12 alleviate the conditions which were described above as treatable by 13 retinoids, to be co-administered with retinoids to eliminate or reduce 14 side effects of retinoids, or to treat retinoid or Vitamin A overdose or poisoning.
16 BIOLOGICAL ACTIVITY, MODES OF ADMINISTRATION 17 Assay of Retinoid-like or Retinoid Antagonist and Inverse Agonist-like 18 Biological Activity 19 A classic measure of retinoic acid activity involves measuring the effects of retinoic acid on ornithine decarboxylase. The original work 21 on the correlation between retinoic acid and decrease in cell 22 proliferation was done by Verma Boutwell, Cancer Research, 1977, 37, 23 2196-2201. That reference discloses that ornithine decarboxylase 24 (ODC) activity increased precedent to polyamine biosynthesis. It has been established elsewhere that increases in polyamine synthesis can be 26 correlated or associated with cellular proliferation. Thus, if ODC 27 activity could be inhibited, cell hyperproliferation could be modulated.
28 Although all cases for ODC activity increases are unknown, it is known 29 that 12-0-tetradecanoylphorbol-13-acetate (TPA) induces ODC activity.
Retinoic acid inhibits this induction of ODC activity by TPA. An assay WO 98/25875 PCT/US97/22581 1 essentially following the procedure set out in Cancer Research: 2 1662-1670,1975 may be used to demonstrate inhibition of TPA induction 3 of ODC by compounds of this invention. "IC6" is that concentration 4 of the test compound which causes 60% inhibition in the ODC assay.
By analogy, "IC 80 for example, is that concentration of the test 6 compound which causes 80% inhibition in the ODC assay.
7 Other assays described below, measure the ability of the 8 compounds of the present invention to bind to, and/or activate various 9 retinoid receptor subtypes. When in these assays a compound binds to o1 a given receptor subtype and activates the transcription of a reporter 11 gene through that subtype, then the compound is considered an agonist 12 of that receptor subtype. Conversely, a compound is considered an 13 antagonist of a given receptor subtype if in the below described 14 co-tranfection assays the compound does not cause significant 1i transcriptional activation of the receptor regulated reporter gene, but 16 nevertheless binds to the receptor with a K, value of less than 17 approximately 1 micromolar. In the below described assays the ability 18 of the compounds to bind to RAR,, RAR 0 RARy, RXRt, RXR, and 19 RXRr receptors, and the ability or inability of the compounds to activate transcription of a reporter gene through these receptor subtypes 21 can be tested.
22 Specifically, a chimeric receptor transactivation assay which tests 23 for agonist-like activity in the RAR., RAR,, RARy, RXR, receptor 24 subtypes, and which is based on work published by Feigner P. L. and Holm M. (1989) Focus, 11 2 is described in detail in United States 26 Patent No. 5,455,265 the specification of which is hereby expressly 27 incorporated by reference.
28 A boloreceptor transactivation assay and a ligand binding assay 29 which measure the antagonist/agonist like activity of the compounds of the invention, or their ability to bind to the several retinoid receptor WO 98/25875 PCT/US97/22581 11 1 subtypes, respectively, are described in published PCT Application No.
2 WO W093/11755 (particularly on pages 30 33 and 37 41) published 3 on June 24, 1993, the specification of which is also incorporated herein 4 by reference. A description of the holoreceptor transactivation assay is also provided below.
6 HOLORECEPTOR TRANSACTIVATION
7 CV1 cells (5,000 cells/well) were transfected with an RAR 8 reporter plasmid MTV-TREp-LUC (50 ng) along with one of the RAR 9 expression vectors (10 ng) in an automated 96-well format by the calcium phosphate procedure of Heyman et al. Cell 68, 397 406, 11 (1992). For RXR, and RXR, transactivation assays, an RXR-responsive 12 reporter plasmid CRBPII-tk-LUC (50 ng) along with the appropriate 13 RXR expression vectors (10 ng) was used substantially as described by 14 Hevman et al. above, and Allegretto et al. J. Biol. Chem. 268, 26625 1i 26633. For RXR, transactivation assays, an RXR-responsive reporter 16 plasmid CPRE-tk-LUC (50 mg) along with RXR, expression vector 17 mg) was used as described in above. These reporters contain DRI is elements from human CRBPII and certain DRI elements from 19 promoter, respectively. (see Mangelsdorf et al. The Retinoids: Biology, Chemistry and Medicine, pp 319 349, Raven Press Ltd., New York and 21 Hevman et al., cited above) A B-galactosidase (50 ng) expression 22 vector was used as an internal control in the transfections to normalize 23 for variations in transfection efficiency. The cells were transfected in 24 triplicate for 6 hours, followed by incubation with retinoids for 36 hours, and the extracts were assayed for luciferase and B-galactosidase 26 activities. The detailed experimental procedure for holoreceptor 27 transactivations has been described in Hevman et al. above, and 28 Allegretto et al. cited above. The results obtained in this assay are 29 expressed in ECo 0 numbers, as they are also in the chimeric receptor transactivation assay. The Heyman et al. Cell 68, 397 406, Allegretto WO 98/25875 PCT/US97/22581 12 1 et al. J. Biol. Chem. 268, 26625 26633, and Mangelsdorf et al. The 2 Retinoids: Biology, Chemistry and Medicine, pp 319 349, Raven Press 3 Ltd., New York, are expressly incorporated herein by reference. The 4 results of ligand binding assay are expressed in Kd numbers. (See s Cheng et al. Biochemical Pharmacology Vol. 22 pp 3099-3108, expressly 6 incorporated herein by reference.) 7 Table 1 shows the results of the ligand binding assay for certain 8 exemplary compounds of the invention for the receptor subtypes in the 9 RAR group.
TABLE 1 11 Ligand Binding Assay 12 13 Compound Kd (nanomolar, nM) 14 No. RAR& RARP RARy 2 13 4 7 16 4 15 6 11 17 12 17 12 33 18 19 Inverse agonists are ligands that are capable of inhibiting the basal receptor activity of unliganded receptors. Recently, retinoic acid 21 receptors (RARs) have been shown to be responsive to retinoid inverse 22 agonists in regulating basal gene transcriptional activity. Moreover, the 23 biological effects associated with retinoid inverse agonists are distinct 24 from those of retinoid agonists or antagonists. For example, RAR inverse agonists, but not RAR neutral antagonists, cause a dose- 26 dependent inhibition of the protein MRP-8 in cultured human 27 keratinocytes differentiated with serum. MRP-8 is a specific marker of 28 cell differentiation, which is also highly expressed in psoriatic epidermis, 29 but is not detectable in normal human skin. Thus, retinoid inverse agonists may offer a unique way of treating diseases such as psoriasis.
31 The activity of retinoid inverse agonists can be tested by the WO 98/25875 PCT/US97/22581 13 1 procedure of Klein et al. J. Biol. Chem. 271, 22692 22696 (1996) which 2 is expressly incorporated herein by reference.
3 In this assay, retinoid inverse agonists are able to repress the 4 basal activity of a RARy-VP-16 chimeric receptor where the s constituitively active domain of the herpes simplex virus (HSV) VP-16 is 6 fused to the N-terminus of RARy. CV-1 cells are cotransfected with 7 RARy-VP-16, an ER-RXRa chimeric receptor and an ERE-tk-Luc 8 chimeric reporter gene to produce a basal level of luciferase activity, as 9 shown by Nagpal et al. EMBO J. 12, 2349 -2360 (1933) expressly incorporated herein by reference. Retinoid inverse agonists are able to 11 inhibit the basal luciferase activity in these cells in a dose dependent 12 manner and ICo 0 s measured. In this assay, Compound 2 had an IC 5 0 of 13 1.0 nM.
14 Modes of Administration is The compounds of this invention may be administered 16 systemically or topically, depending on such considerations as the 17 condition to be treated, need for site-specific treatment, quantity of is drug to be administered, and numerous other considerations.
19 In the treatment of dermatoses, it will generally be preferred to administer the drug topically, though in certain cases such as treatment 21 of severe cystic acne or psoriasis, oral administration may also be used.
22 Any common topical formulation such as a solution, suspension, gel, 23 ointment, or salve and the like may be used. Preparation of such 24 topical formulations are well described in the art of pharmaceutical formulations as exemplified, for example, by Remington's 26 Pharmaceutical Science, Edition 17, Mack Publishing Company, Easton, 27 Pennsylvania. For topical application, these compounds could also be 28 administered as a powder or spray, particularly in aerosol form. If the 29 drug is to be administered systemically, it may be confected as a powder, pill, tablet or the like or as a syrup or elixir suitable for oral WO 98/25875 PCT/US97/22581 14 1 administration. For intravenous or intraperitoneal administration, the 2 compound will be prepared as a solution or suspension capable of being 3 administered by injection. In certain cases, it may be useful to 4 formulate these compounds by injection. In certain cases, it may be useful to formulate these compounds in suppository form or as extended 6 release formulation for deposit under the skin or intramuscular 7 injection.
8 Other medicaments can be added to such topical formulation for 9 such secondary purposes as treating skin dryness; providing protection against light; other medications for treating dermatoses; medicaments 11 for preventing infection, reducing irritation, inflammation and the like.
12 Treatment of dermatoses or any other indications known or 13 discovered to be susceptible to treatment by retinoic acid-like 14 compounds will be effected by administration of the therapeutically effective dose of one or more compounds of the instant invention. A 16 therapeutic concentration will be that concentration which effects 17 reduction of the particular condition, or retards its expansion. In a18 certain instances, the compound potentially may be used in prophylactic 19 manner to prevent onset of a particular condition.
A useful therapeutic or prophylactic concentration will vary from 21 condition to condition and in certain instances may vary with the 22 severity of the condition being treated and the patient's susceptibility to 23 treatment. Accordingly, no single concentration will be uniformly 24 useful, but will require modification depending on the particularities of the disease being treated. Such concentrations can be arrived at 26 through routine experimentation. However, it is anticipated that in the 27 treatment of, for example, acne, or similar dermatoses, that a 28 formulation containing between 0.01 and 1.0 milligrams per milliliter of 29 formulation will constitute a therapeutically effective concentration for total application. If administered systemically, an amount between 0.01 WO 98/25875 PCT/US97/22581 1 and 5 mg per kg per day of body weight would be expected to effect a 2 therapeutic result in the treatment of many diseases for which these 3 compounds are useful.
4 The partial or pan retinoid antagonist and/or retinoid inverse s agonist compounds of the invention, when used to take advantage of 6 their antagonist and/or inverse agonist property, can be co-administered 7 to mammals, including humans, with retinoid agonists and, by means of 8 pharmacological selectivity or site-specific delivery, preferentially 9 prevent the undesired effects of certain retinoid agonists. The antagonist and/or inverse agonist compounds of the invention can also 11 be used to treat Vitamin A overdose, acute or chronic, resulting either 12 from the excessive intake of vitamin A supplements or from the 13 ingestion of liver of certain fish and animals that contain high levels of 14 Vitamin A. Still further, the antagonist and/or inverse agonist 1i compounds of the invention can also be used to treat acute or chronic 16 toxicity caused by retinoid drugs. It has been known in the art that the 17 toxicities observed with hypervitaminosis A syndrome (headache, skin e1 peeling, bone toxicity, dyslipidemias) are similar or identical with 19 toxicities observed with other retinoids, suggesting a common biological cause, that is RAR activation. Because the antagonist or inverse agonist 21 compounds of the present invention block or diminish RAR activation, 22 they are suitable for treating the foregoing toxicities.
23 Generally speaking, for therapeutic applications in mammals, the 24 antagonist and/or inverse agonist compounds of the invention can be admistered enterally or topically as an antidote to vitamin A, or 26 antidote to retinoid toxicity resulting from overdose or prolonged 27 exposure, after intake of the causative factor (vitamin A, vitamin A 28 precursor, or other retinoid) has been discontinued. Alternatively, the 29 antagonist and/or inverse agonist compounds of the invention are co-administered with retinoid drugs, in situations where the retinoid WO 98/25875 PCT/US97/22581 16 1 provides a therapeutic benefit, and where the co-administered 2 antagonist and/or inverse agonist compound alleviates or eliminates one 3 or more undesired side effects of the retinoid. For this type of 4 application the antagonist and/or inverse agonist compound may be s administered in a site-specific manner, for example as a topically 6 applied cream or lotion while the co-administered retinoid may be given 7 enterally. For therapeutic applications the antagonist compounds of 8 the invention, like the retinoid agonists compounds, are incorporated 9 into pharmaceutical compositions, such as tablets, pills, capsules, solutions, suspensions, creams, ointments, gels, salves, lotions and the 11 like, using such pharmaceutically acceptable excipients and vehicles 12 which per se are well known in the art. For topical application, the 13 antagonist and/or inverse agonist compounds of the invention could also 14 be administered as a powder or spray, particularly in aerosol form. If the drug is to be administered systemically, it may be confected as a 16 powder, pill, tablet or the like or as a syrup or elixir suitable for oral 17 administration. For intravenous or intraperitoneal administration, the 18 compound will be prepared as a solution or suspension capable of being 19 administered by injection. In certain cases, it may be useful to formulate these compounds by injection. In certain cases, it may be 21 useful to formulate these compounds in suppository form or as extended 22 release formulation for deposit under the skin or intramuscular 23 injection.
24 The antagonist and/or inverse agonist compounds also, like the retinoid agonists of the invention, will be administered in a 26 therapeutically effective dose. A therapeutic concentration will be that 27 concentration which effects reduction of the particular condition, or 28 retards its expansion. When co-administering the compounds of the 29 invention to block retinoid-induced toxicity or side effects, the antagonist and/or inverse agonist compounds of the invention are used WO 98/25875 PCT/US97/22581 17 1 in a prophylactic manner to prevent onset of a particular condition, such 2 as skin irritation.
3 A useful therapeutic or prophylactic concentration will vary from 4 condition to condition and in certain instances may vary with the severity of the condition being treated and the patient's susceptibility to 6 treatment. Accordingly, no single concentration will be uniformly 7 useful, but will require modification depending on the particularities of 8 the chronic or acute retinoid toxicity or related condition being treated.
9 Such concentrations can be arrived at through routine experimentation.
However, it is anticipated that a formulation containing between 0.01 11 and 1.0 milligrams of the active compound per mililiter of formulation 12 will constitute a therapeutically effective concentration for total 13 application. If administered systemically, an amount between 0.01 and 14 mg per kg per day of body weight would be expected to effect a 1i therapeutic result.
16 GENERAL EMBODIMENTS AND SYNTHETIC METHODOLOGY 17 Definitions 18 The term alkyl refers to and covers any and all groups which are 19 known as normal alkyl, branched-chain alkyl and cycloalkyl. The term alkenyl refers to and covers normal alkenyl, branch chain alkenyl and 21 cycloalkenyl groups having one or more sites of unsaturation. Similarly, 22 the term alkynyl refers to and covers normal alkynyl, and branch chain 23 alkynyl groups having one or more triple bonds.
24 Lower alkyl means the above-defined broad definition of alkyl groups having 1 to 6 carbons in case of normal lower alkyl, and as 26 applicable 3 to 6 carbons for lower branch chained and cycloalkyl 27 groups. Lower alkenyl is defined similarly having 2 to 6 carbons for 28 normal lower alkenyl groups, and 3 to 6 carbons for branch chained and 29 cyclo- lower alkenyl groups. Lower alkynyl is also defined similarly, having 2 to 6 carbons for normal lower alkynyl groups, and 4 to 6 WO 98/25875 PCT/US97/22581 18 1 carbons for branch chained lower alkynyl groups.
2 The term "ester" as used here refers to and covers any compound 3 falling within the definition of that term as classically used in organic 4 chemistry. It includes organic and inorganic esters. Where B of s Formula 1 is -COOH, this term covers the products derived from 6 treatment of this function with alcohols or thiols preferably with 7 aliphatic alcohols having 1-6 carbons. Where the ester is derived from 8 compounds where B is -CH 2 OH, this term covers compounds derived 9 from organic acids capable of forming esters including phosphorous based and sulfur based acids, or compounds of the formula 11 -CH 2 OCOR, where R 1 is any substituted or unsubstituted aliphatic, 12 aromatic, heteroaromatic or aliphatic aromatic group, preferably with 13 1-6 carbons in the aliphatic portions.
14 Unless stated otherwise in this application, preferred esters are derived from the saturated aliphatic alcohols or acids of ten or fewer 16 carbon atoms or the cyclic or saturated aliphatic cyclic alcohols and 17 acids of 5 to 10 carbon atoms. Particularly preferred aliphatic esters are s1 those derived from lower alkyl acids and alcohols. Also preferred are 19 the phenyl or lower alkyl phenyl esters.
Amides has the meaning classically accorded that term in organic 21 chemistry. In this instance it includes the unsubstituted amides and all 22 aliphatic and aromatic mono- and di- substituted amides. Unless stated 23 otherwise in this application, preferred amides are the mono- and 24 di-substituted amides derived from the saturated aliphatic radicals of ten or fewer carbon atoms or the cyclic or saturated aliphatic-cyclic radicals 26 of 5 to 10 carbon atoms. Particularly preferred amides are those 27 derived from substituted and unsubstituted lower alkyl amines. Also 28 preferred are mono- and disubstituted amides derived from the 29 substituted and unsubstituted phenyl or lower alkylphenyl amines.
Unsubstituted amides are also preferred.
WO 98/25875 PCT/US97/22581 19 1 Acetals and ketals include the radicals of the formula-CK where 2 K is (-OR) 2 Here, R is lower alkyl. Also, K may be -OR 7 0- where R 7 3 is lower alkyl of 2-5 carbon atoms, straight chain or branched.
4 A pharmaceutically acceptable salt may be prepared for any s compounds in this invention having a functionality capable of forming a 6 salt, for example an acid functionality. A pharmaceutically acceptable 7 salt is any salt which retains the activity of the parent compound and a does not impart any deleterious or untoward effect on the subject to 9 which it is administered and in the context in which it is administered.
Pharmaceutically acceptable salts may be derived from organic or 11 inorganic bases. The salt may be a mono or polyvalent ion. Of 12 particular interest are the inorganic ions, sodium, potassium, calcium, 13 and magnesium. Organic salts may be made with amines, particularly 14 ammonium salts such as mono-, di- and trialkyl amines or ethanol amines. Salts may also be formed with caffeine, tromethamine and 16 similar molecules. Where there is a nitrogen sufficiently basic as to be 17 capable of forming acid addition salts, such may be formed with any 18 inorganic or organic acids or alkylating agent such as methyl iodide.
19 Preferred salts are those formed with inorganic acids such as hydrochloric acid, sulfuric acid or phosphoric acid. Any of a number of 21 simple organic acids such as mono-, di- or tri- acid may also be used.
22 Some of the compounds of the present invention may have trans 23 and cis (E and Z) isomers. In addition, the compounds of the present 24 invention may contain one or more chiral centers and therefore may exist in enantiomeric and diastereomeric forms. The scope of the 26 present invention is intended to cover all such isomers per se, as well as 27 mixtures of cis and trans isomers, mixtures of diastereomers and 28 racemic mixtures of enantiomers (optical isomers) as well. In the 29 present application when no specific mention is made of the configuration (cis, trans, or R or S) of a compound (or of an asymmetric WO 98/25875 PCT/US97/22581 1 carbon) then a mixture of such isomers, or either one of the isomers is 2 intended. In a similar vein, when in the chemical structural formulas of 3 this application a straight line representing a valence bond is drawn to 4 an asymmetric carbon, then isomers of both R and S configuration, as well as their mixtures are intended.
6 The numbering system used in the naming of the compounds of 7 the present invention, as well as of the intermediate compounds utilized 8 in the synthetic routes leading to the compounds of the invention, is 9 illustrated below for 3,4-dihydroanthracene, benzo[1,2-g]-chrom-3-ene, benzo[1, 2 -g]-thiochrom-3-ene and benzo[1,2-g]-1,2-dihydroquinoline and 11 for 3 4 -dihydro-4,4-dimethyl-7-bromo-1(2H)-naphthalenone.
12 13 1 10 9 4 5 6 4 5 6 14 A A
4 5 6 1 10 9 10 9 16 17 18 3,4-dihydroanthracene benzo[1,2-g]-chrom-3-en benzo[1,2-g]-thiochrom-3-en 19 21 4 5 6 0 22 3 A B C 7 2 87 Br 1 10 9 4 5 6 24 26 benzo[1,2-g]-1,2-dihydroquinoline 3,4-dihydro-4,4-dimethyl-7-bromo-1(2H)- 27 naphthalenone 28 Generally speaking, the 3,4-dihydroanthracene compounds of the 29 invention are prepared in synthetic steps which usually first involve the multistep preparation of a 3,4-dihydronaphthalene derivative that WO 98/25875 PCT/US97/22581 21 1 already includes the desired R 2 R3 and R4 substituents and an 2 aldehyde function in the 6 or 7-position of the 3,4-dihydronaphthalene 3 nucleus. For the preparation of benzo[1,2-g]-chrom-3-ene, benzo[1,2- 4 g]-thiochrom-3-ene and benzo[1,2-g]-1,2-dihydroquinoline derivatives of the invention, the first (usually multi-step) procedure involves the 6 preparation of a chrom-3-ene, thiochrom-3-ene or 1,2-dihydroquinoline 7 derivative which already includes the desired R 1
3 and R4 8 substituents of the compounds of the invention, and an aldehyde 9 function in the 6 or 7-position of the chrom-3-ene, thiochrom-3-ene or 1,2-dihydroquinoline nucleus. The aldehyde is then reacted in a Homer 11 Emmons or Wittig, or like reaction with an aryl or heteroaryl 12 phosphonate that carries a side chain capable of cyclizing with the 13 carbocyclic aromatic group of the 3,4-dihydronaphthalene, chrom-3-ene, 14 thiochrom-3-ene or 1,2-dihydroquinoline intermediate. The latter cyclization reaction forms the ring of the 3,4-dihydroanthracene, 16 benzo[1,2-g]-chrom-3-ene, benzo[1,2-g]-thiochrom-3-ene and benzo[1,2- 17 g]-1,2-dihydroquinoline compounds of the invention.
18 Details of the above-outlined generalized synthetic schemes are 19 provided below in connection with the description of the specific embodiments and specific examples.
21 The synthetic methodology employed for the synthesis of the 22 compounds of the present invention may also include transformations of 23 the group designated -A-B in Formula 1. Generally speaking, these 24 transformations involve reactions well within the skill of the practicing organic chemist. In this regard the following well known and published 26 general principles and synthetic methodology are briefly described.
27 Carboxylic acids are typically esterified by refluxing the acid in a 28 solution of the appropriate alcohol in the presence of an acid catalyst 29 such as hydrogen chloride or thionyl chloride. Alternatively, the carboxylic acid can be condensed with the appropriate alcohol in the WO 98/25875 PCT/US97/22581 22 1 presence of dicyclohexylcarbodiimide (DCC) and 4- 2 (dimethylamino)pyridine (DMAP). The ester is recovered and purified 3 by conventional means. Acetals and ketals are readily made by the 4 method described in March, "Advanced Organic Chemistry," 2nd Edition, McGraw-Hill Book Company, p 810). Alcohols, aldehydes and 6 ketones all may be protected by forming respectively, ethers and esters, 7 acetals or ketals by known methods such as those described in McOmie, 8 Plenum Publishing Press, 1973 and Protecting Groups, Ed. Greene, 9 John Wiley Sons, 1981.
To increase the value of q in the compounds of the invention 11 (or precursors thereof) before affecting the coupling or linkage in a 12 Homer Emmons or like reaction with the aldehyde on the 3,4- 13 dihydronaphthalene, chrom-3-ene, thiochrom-3-ene or 1,2- 14 dihydroquinoline nucleus (where such compounds are not available from a commercial.source) aromatic or heteroaromatic carboxylic acids 16 are subjected to homologation by successive treatment under 17 Arndt-Eistert conditions or other homologation procedures.
18 Alternatively, derivatives which are not carboxylic acids may also be 19 homologated by appropriate procedures. The homologated acids can then be esterified by the general procedure outlined in the preceding 21 paragraph and converted into phosphonates of phosphonium salts 22 suitable for the Homer Emmons or Wittig reaction. Compounds of the 23 invention as set forth in Formula 1 (or precursors thereof) where A is 24 an alkenyl group having one or more double bonds can be made for example, by synthetic schemes well known to the practicing organic 26 chemist; for example by Wittig and like reactions, or by introduction of 27 a double bond by elimination of halogen from an 28 alpha-halo-arylalkyl-carboxylic acid, ester or like carboxaldehyde.
29 Compounds of the invention or precursors thereof, where the A group has a triple (acetylenic) bond, can be made by reaction of a WO 98/25875 PCT/US97/22581 23 1 corresponding aromatic methyl ketone with strong base, such as lithium 2 diisopropylamide, reaction with diethyl chlorophosphate and subsequent 3 addition of lithium diisopropylamide.
4 The acids and salts derived from compounds of the invention are s readily obtainable from the corresponding esters. Basic saponification 6 with an alkali metal base will provide the acid. For example, an ester of 7 the invention may be dissolved in a polar solvent such as an alkanol, a preferably under an inert atmosphere at room temperature, with about 9 a three molar excess of base, for example, lithium hydroxide or potassium hydroxide. The solution is stirred for an extended period of 11 time, between 15 and 20 hours, cooled, acidified and the hydrolysate 12 recovered by conventional means.
13 The amide may be formed by any appropriate amidation means 14 known in the art from the corresponding esters or carboxylic acids. One way to prepare such compounds is to convert an acid to an acid chloride 16 and then treat that compound with ammonium hydroxide or an 17 appropriate amine. For example, the ester is treated with an alcoholic 18 base solution such as ethanolic KOH (in approximately a 10% molar 19 excess) at room temperature for about 30 minutes. The solvent is removed and the residue taken up in an organic solvent such as diethyl 21 ether, treated with a dialkyl formamide and then a 10-fold excess of 22 oxalyl chloride. This is all effected at a moderately reduced 23 temperature between about -10 degrees and +10 degrees C. The last 24 mentioned solution is then stirred at the reduced temperature for 1-4 hours, preferably 2 hours. Solvent removal provides a residue which is 26 taken up in an inert organic solvent such as benzene, cooled to about 0 27 degrees C and treated with concentrated ammonium hydroxide. The 28 resulting mixture is stirred at a reduced temperature for 1 4 hours.
29 The product is recovered by conventional means.
Alcohols are made by converting the corresponding acids to the WO 98/25875 PCT/US97/22581 24 1 acid chloride with thionyl chloride or other means March, "Advanced 2 Organic Chemistry", 2nd Edition, McGraw-Hill Book Company), then 3 reducing the acid chloride with sodium borohydride (March, Ibid, pg.
4 1124), which gives the corresponding alcohols. Alternatively, esters may be reduced with lithium aluminum hydride at reduced temperatures.
6 Alkylating these alcohols with appropriate alkyl halides under 7 Williamson reaction conditions (March, Ibid, pg. 357) gives the 8 corresponding ethers. These alcohols can be converted to esters by 9 reacting them with appropriate acids in the presence of acid catalysts or dicyclohexylcarbodiimide and dimethylaminopyridine.
11 Aldehydes can be prepared from the corresponding primary 12 alcohols using mild oxidizing agents such as pyridinium dichromate in 13 methylene chloride (Corey, E. Schmidt, Tet. Lett., 399, 1979), or 14 dimethyl sulfoxide/oxalyl chloride in methylene chloride (Omura, K., Swern, Tetrahedron, 1978, 34, 1651).
16 Ketones can be prepared from an appropriate aldehyde by 17 treating the aldehyde with an alkyl Grignard reagent or similar reagent is followed by oxidation.
19 Acetals or ketals can be prepared from the corresponding aldehyde or ketone by the method described in March, Ibid, p 810.
21 Compounds of the invention, or precursors thereof, where B is 22 H can be prepared from the corresponding halogenated aromatic or 23 heteroaromatic compounds, preferably where the halogen is I.
24 SPECIFIC EMBODIMENTS With reference to the symbol Y in Formula 1, the preferred 26 compounds of the invention are those where Y is phenyl, naphthyl, 27 pyridyl, thienyl or furyl. Even more preferred are compounds where Y 28 is phenyl. As far as substititutions on the Y (phenyl) and Y (pyridyl) 29 groups are concerned, compounds are preferred where the phenyl group is 1,4 (para) substituted and where the pyridine ring is 2,5 substituted.
WO 98/25875 PCT/US97/22581 1 (Substitution in the 2,5 positions in the "pyridine" nomenclature 2 corresponds to substitution in the 6-position in the "nicotinic acid" 3 nomenclature.) In the presently preferred compounds of the invention 4 there is no R 2 substituent on the Y group.
The A-B group of the preferred compounds is (CH,)qCOOH or 6 (CH 2 )q-COOR, where R 8 is defined as above. Even more preferably q 7 is zero and R 8 is lower alkyl.
8 The aromatic carbocyclic portions (B and C rings) of the 3,4- 9 dihydroanthracene moiety, or of the benzo[1,2-g]-chrom-3-ene, benzo[1,2-g]-thiochrom-3-ene and benzo[1,2-g]-1,2-dihydroquinoline 11 moiety of the compounds of the invention (as applicable) are 12 preferably substituted only by the -Y(R 2 )m-A-B group. In other words, 13 in the preferred compounds there is no R, substituent (other than 14 hydrogen) on the aromatic carbocyclic portion of the condensed ring system. Similarly, in the preferred compounds of the invention there is 16 no R 3 substituent (other than hydrogen).
17 The moiety designated X, in Formula 1 is preferably -C(Ri) 2 18 C(Ri) 2 -C(Ri) 2 -C(Ri) 2 or -C(Ri) 2 and R, is preferably 19 H or methyl. The -Y(R 2 )m-A-B group is preferably attached to the 8position of the 3,4-dihydroanthracene nucleus and to the 7-position of 21 the benzo[1,2-g]-chrom-3-ene, benzo[1,2-g]-thiochrom-3-ene and 22 benzo[1,2-g]-1,2-dihydroquinoline nucleus, as applicable.
23 Referring now to the R 4 substituent in the compounds of Formula 24 1, compounds are preferred where this substituent is phenyl, Rssubstituted phenyl, pyridyl, Rs-substituted pyridyl, thienyl, or Rs- 26 substituted thienyl. Even more preferred are compounds where the R4 27 substituent is phenyl, 4-methylphenyl, 3-pyridyl and particularly 6- 28 methyl-3-pyridyl, 2-thienyl and particularly 5-methyl-2-thienyl.
29 The most preferred compounds of the invention are listed below in Table 2 with reference to Formula 2 or Formula 3 as applicable.
WO 98/25875 WO 9825875PCTIUS97/22581 26 Formula 2 Formula 3 TABLE 2 Compound Formula X R4 8 No. 4R 1 2 4-methyiphenyl Et 2 2 4-methyiphenyl
3 2 5-methyl(2-thienyl) Et 4 2 5-methyl(2-thienyl)
2 6-methyl(3-pyridyl) Et 6 2 6-methyl(3-pyridyl)
7 3 S 4-methyiphenyl Et 8 3 S 4-methyiphenyl
9 3 0 4-methylphenyl Et 3 0 4-methylphenyl
11 3 0 5-methyl(2-thienyl) Et 12 3 0 5-methyl(2-thienyl)
13 3 S 5-methyl (2-th ienyl) Et 1j4 3 1S t5-methl(2-thienyl)
WO 98/25875 PCT/US97/22581 27 The compounds of this invention can be made by the general procedures outlined above under the title ""GENERAL EMBODIMENTS AND SYNTHETIC METHODOLOGY". The following chemical pathways represent the presently preferred synthetic routes to certain classes of the compounds of the invention and to certain specific exemplary compounds. However, the synthetic chemist will readily appreciate that the conditions set out here for these specific embodiments can be generalized to any and all of the compounds represented by Formula 1.
-9- O DiBAl-H Formula 5 Formula4 IPd(0), MeOH,
Formula (EtO)2POCH-Y-A-B BuLi, cH2CH(OMe)2 Formula 7
TOMe OMe Formula6 Homologs and Derivatives Formula 8 SnCl4 R4 W Y, A
o B Formula 9 Reaction Scheme 1 WO 98/25875 PCT/US97/22581 28 1 Referring now to Reaction Scheme 1 a synthetic process is 2 described whereby compounds of the invention are obtained in which, 3 with reference to Formula 1, X 1 is -C(R 1 2 C(Ri) 2 and the Y group is 4 phenyl, naphthyl or heteroaryl. In other words Reaction Scheme 1 describes an example of a synthetic route for preparing compounds of 6 the invention which are 3,4-dihydroanthracene derivatives. The reaction 7 scheme discloses this synthetic route for the preferred examples in 8 which the Y group is coupled to the 8 position of the 3,4- 9 dihydroanthracene nucleus, and the 4-position bears two (geminal) methyl substituents. Nevertheless, those skilled in the art will readily 11 understand that the synthetic steps of Reaction Scheme 1 can be readily 12 modified, within the skill of the art, to yield other 3,4-dihydroanthracene 13 compounds of the invention. The starting materials for the synthetic 14 route of Reaction Scheme 1 are 6 or 7-bromo (or like halogeno) substituted 1-(2H)-naphthalenones. Specifically, for the examplary 16 synthetic route illustrated in Reaction Scheme 1 the starting material is 17 3,4-dihydro-4,4-dimethyl-7-bromo-1(2H)-naphthalenone (Compound A).
18 Compound A can be obtained in accordance with the chemical scientific 19 (Johnson et al. J. Med. Chem 1995, 38, 4764-4767) and patent (United States Patent No. 5,543,534) literature. The Johnson et al.
21 publication and the specification of United States Patent No. 5,543,534 22 are expressly incorporated herein by reference. Another example for 23 the starting material in Reaction Scheme 1 is 3,4-dihydro-4,4-dimethyl-6- 24 bromo-1(2H)-naphthalenone. The latter compound, when subjected to the reactions disclosed in this scheme, gives rise to 3,4- 26 dihydroanthracene compounds of the invention where the Y group is 27 coupled to the 7-position of the 3,4-dihydroanthracene nucleus. 3,4- 28 Dihydro-4,4-dimethyl-6-bromo-1(2H)-naphthalenone can also be 29 obtained in accordance with the chemical scientific (Mathur et al.
Tetrahedron, 41, 1509 1516 (1985)) and patent (United States Patent WO 98/25875 PCT/US97/22581 29 1 No. 5,543,534) literature.
2 In accordance with Reaction Scheme 1, 3,4-dihydro-4,4-dimethyl-7- 3 bromo-1(2H)-naphthalenone (Compound A) is reacted with a Grignard 4 reagent of the formula R 4 -Mg-X 2 where R 4 is an aryl or heteroaryl s group as defined in connection with Formula 1, and X 2 is halogen, 6 preferably bromine. The product of the Grignard (or analogous) 7 reaction is a tertiary alcohol (not shown in the reaction scheme) which 8 is dehydrated by treatment with acid, to give a 1-aryl or 1- heteroaryl-7- 9 bromo-3,4-dihydronaphthalene derivative of Formula 4. An example for a Grignard reagent used in the synthesis of preferred compounds of the 11 invention is the reagent obtained from 4-bromotoluene with magnesium.
12 An alternative method for obtaining the 1-aryl or 1- heteroaryl-7-bromo- 13 3,4-dihydronaphthalene derivatives of Formula 4 is a reaction between 14 an aryl or heteroaryl halide of the formula R 4
2 (R4 and X 2 are defined is as above, X 2 is preferably Br) with Compound A in the presence of 16 strong base, such as n-butyl lithium. A suitable reagent for this reaction 17 is, for example, 2-methyl-5-bromopyridine. As still another alternative, ie Compound A is reacted with the lithium (or other suitable metal) salt of 19 the formula R 4 -Li, (R4 is defined as above), that can be obtained by reaction between a heteroaryl compound (such as 2-methylthiophene) 21 and n-butyl lithium.
22 In the next step of the reaction sequence disclosed in Reaction 23 Scheme 1, the 1-aryl or 1- heteroaryl-7-bromo-3,4-dihydronaphthalene 24 derivatives of Formula 4 are reacted with dimethylformamide (DMF) in the presence of tertiary-butyl lithium to provide the 1-aryl or 1- 26 heteroaryl-3,4-dihydronaphthalene-7-aldehydes of Formula 5. The 27 aldehyde compounds of Formula 5 can also be obtained by first 28 converting the 7-bromo function of the compounds of Formula 4 into a 29 carboxylic acid ester function or carboxylic acid, to give the 1-aryl or 1heteroaryl-3,4-dihydronaphthalene-7- carboxylic acid esters (or acids, not WO 98/25875 PCTIUS97/22581 1 shown in the scheme) of Formula 6. The carboxylic acid methyl ester 2 derivative is obtained, for example by reaction with carbon monoxide 3 and methanol in the presence of palladium[2]bis(triphenylphoshine) 4 chloride and 1,3-bis(diphenylphosphino)propane, as shown in the scheme. The compounds of Formula 6 are reduced with a suitable 6 reducing agent, such as diisobutyl aluminum hydride (DiBAl-H) to 7 provide the 1-aryl or 1- heteroaryl-3,4-dihydronaphthalene-7-aldehydes 8 of Formula 9 The aldehydes of Formula 5 are subjected to a Homer Emmons type reaction, in the presence of strong base such as n-butyl lithium in 11 hexane, with a 1-aryl or 1-heteroaryl 1-diethoxyphosphoryl-3,3- 12 dimethoxypropane derivative of Formula 7. An example of the 13 phosphonate compound, which is used in the preparation of several 14 preferred compounds of the invention, is ethyl 4-(diethoxyphosphoryl- 3,3-dimethoxypropyl)benzoate. Ethyl 4-(diethoxyphosphoryl-3,3- 16 dimethoxypropyl)benzoate is available in accordance with the procedure 17 of EPO Application No. 0 210 929 (published on February 4, 1987, 18is Shroot et at) which is incorporated herein by reference. In accordance 19 with the Shroot et al. reference the reagent ethyl 4-(diethoxyphosphoryl- 3,3-dimethoxypropyl)benzoate is made starting with ethyl 4- 21 bromobenzoate that is reacted with dimetyl acetal of acryl aldehyde, the 22 product is hydrogenated and subsequently brominated (with N-bromo 23 succinimide) and thereafter reacted with triethylphosphite.
24 Other examples for the phoshonates of Formula 7 are ethyl 2- (diethoxyphosphoryl-3,3-dimethoxypropyl)pyridine-5-carboxylate, ethyl 26 2 -(diethoxyphosphoryl-3,3-dimethoxypropyl)pyridine-6-carboxylate, ethyl 27 2 -(diethoxyphosphoryl-3,3-dimethoxypropyl)thiophene-4-carboxylate, 28 ethyl 2-(diethoxyphosphoryl-3,3-dimethoxypropyl)thiophene-5- 29 carboxylate, ethyl 2-(diethoxyphosphoryl-3,3-dimethoxypropyl)furan-4carboxylate, ethyl 2-(diethoxyphosphoryl-3,3-dimethoxypropyl)furan-5- WO 98/25875 PCTIUS97/22581 31 1 carboxylate. These and analogous phosphonate reagents within the 2 scope of Formula 7 can be obtained by appropriate modification of the 3 procedure described in the Shroot et al. reference.
4 The product of the Homer Emmons reaction between the 1-aryl or 1heteroaryl-3,4-dihydronaphthalene-7-aldehydes of Formula 5 and the 1- 6 aryl or 1-heteroaryl 1-diethoxyphosphoryl-3,3-dimethoxypropane 7 derivative of Formula 7 is a disubstituted ethene compound of Formula 8 8. Those skilled in the art will readily understand that instead of a 9 Homer Emmons reaction, a Wittig reaction can also be employed, utilizing the appropriate phosphonium derivative, to provide compounds 11 of Formula 8.
12 The disubstituted ethene compounds of Formula 8 are cyclized, for 13 example by heating in a neutral solvent (such as dischloromethane), in 14 the presence of SnCl 4 or other suitable Friedel Crafts type catalyst, to form the "C ring" of the 3,4-dihydroanthracene derivatives of the 16 invention, within the scope of Formula 9. The compounds of Formula 17 9 can be converted into further compounds of the invention by reaction 18 well known to the synthetic organic chemist, such as saponification, 19 esterification, amide formation and homologation. These reactions were briefly described above, and the syntheses of these further compounds 21 of the invention is indicated in Reaction Scheme 1 as conversion to 22 "HOMOLOGS AND DERIVATIVES'.
WO 98/25875 PCT/US97/22581 32 1 2 4 3 Br R4X 2 t-BuLi, t-BuLi or 4 R4H n-Bi n-BuLi, X4 H+
Formula 10 Formula 11 6 8 CHO 9 BuL, H2CH(OMe) 2 OMe Formula 7 Me Formula 12 11 Formula 13 R4 12 13 Y
14 n Homologs and 1 Derivatives Formula 14 16 17 18 REACTION SCHEME 2 19 Reaction Scheme 2 discloses the synthesis of compounds of the invention where with reference to Formula 1 the Xi group is 2 21 2 or -C(Ri) 2 -NR- where the Y group is phenyl, naphthyl or 22 heteroaryl and the R, group is defined as in connection with Formula 1.
23 In other words, Reaction Scheme 2 discloses the preferred synthetic 24 routes to compounds of the invention which are benzo[1,2-g]-chrom-3ene, benzo[1,2-g]-thiochrom-3-ene and benzo[1,2-g]-1,2-dihydroquinoline 26 derivatives. As in Reaction Scheme 1 in this scheme also the 27 description is directed to a synthetic route for the preferred examples in 28 which the Y group is coupled to the 8 position of the tricyclic condensed 29 ring. In these preferred examples the 2-position of the tricyclic condensed ring bears two (geminal) methyl substituents. Nevertheless, WO 98/25875 PCT/US97/22581 33 1 those skilled in the art will readily understand that the synthetic steps of 2 Reaction Scheme 2 can be readily modified, within the skill of the art, 3 to yield other benzo[1,2-g]-chrom-3-ene, benzo[1,2-g]-thiochrom-3-ene 4 and benzo[1,2-g]-1,2-dihydroquinoline compounds of the invention.
6-Bromochroman-4-one, 6-bromothiochroman-4-one and 6-bromo- 6 1, 2 3 4 -tetrahydroquinoline-4-one derivatives of Formula 10 serve as 7 starting materials in the steps shown in Reaction Scheme 1.
8 Specifically, 2 2 -dimethyl-6-bromo-thiochroman-4-one can be obtained 9 from the reaction of thiophenol with 3,3-dimethylacrilic acid, followed by cyclization of the resulting adduct, as is described in detail in the 11 "Specific Examples" section of this application. 2,2-Dimethyl-6- 12 bromochroman-4-one can be obtained in accordance with the procedure 13 of Buckle et al. J. Med. Chem. 1990 33, 3028, which is expressly 14 incorporated herein by reference. 2,2-Dimethyl-6-bromo-1,2,3,4tetrahydroquinoline can be obtained by bromination with N- 16 bromosuccinimide of 2 ,2-dimethyl-1,2,3,4-tetrahydroquinoline that is 17 available in accordance with the chemical literature (Helv. Chim. Acta 18 (1990) 73, 1515-1573).
19 In accordance with Reaction Scheme 2, the 6-bromochroman-4-one, 6-bromothiochroman-4-one or 6-bromo-1,2,3,4-tetrahydroquinoline-4- 21 one derivative of Formula 10 is reacted with a reagent of the formula 22 R 4
2 where X 2 is halogen, preferably bromine, in the presence of 23 strong base, such as tertiary-butyl lithium or normal-butyl lithium. R 4 24 and X, are defined as in connection with Reaction Scheme 1. 4-aryl or 4-heteroaryl 6-bromochrom-3-ene, 4-aryl or 4-heteroaryl 6- 26 bromothiochrom-3-ene or 4-aryl or 4-heteroaryl 6- 27 bromoll,2,dihydroquinoline derivatives of Formula 11 are obtained in 28 this reaction after acid catalyzed dehydration of the tertiary alcohol 29 intermediate that is first formed in the reaction with R 4
Grignard reagent of the formula R 4 -Mg-X 2 or the metal salt, particularly WO 98/25875 PCT/US97/22581 34 1 the lithium salt, of an aryl or heteroaryl compond of the forula R4-Li 2 can also be employed, to yield the 4-aryl or 4-heteroaryl derivatives of 3 Formula 11. The 4-aryl or 4-heteroaryl 6-bromochrom-3-ene, 4-aryl or 4 4-heteroaryl 6-bromothiochrom-3-ene or 4-aryl or 4-heteroaryl 6-bromo- 1,2,dihydroquinoline derivatives of Formula 11 are converted into the 6 aryl or heteroaryl substituted benzo[1,2-g]-chrom-3-ene, benzo[1,2-g]- 7 thiochrom-3-ene and benzo[1,2-g]-1,2-dihydroquinoline compounds of 8 the invention in the same, or substantially the same sequence of 9 reactions, as is described in Reaction Scheme 1. This sequence of reactions is shown in Reaction Scheme 2, and specific examples for their 11 application are described in the "Specific Examples" section. The 12 disubstituted ethene compounds of Formula 13 are usually not isolated 13 in a pure form. Rather they are subjected to a cyclization reaction 14 without purification to provide the compounds of Formula 14, which can be further converted into homologs and derivatives still within the 16 scope of the invention.
17 Compounds of the invention where with reference to Formula 1 the 18 X 1 group is -C(R 1 2 can be made in analogy to the synthetic steps 19 outlined in Reaction Scheme 1, starting with 6-bromo-indan-l-one or from an appropriately subtituted derivative. In these synthetic schemes 21 6-bromo-indan-l-one is used in analogy to 7-bromo-3,4-dihydro-4,4- 22 dimethylnaphthalen-1(2H)-one (Compound A) as a starting material. 6- 23 bromo-3,3-dimethyl-indan-1-one is available accordance with the 24 chemical literature. (See Smith et al. Org. Prep. Proced. Int., 1978, 123-131.) 26 Compounds of the invention where with reference to Formula 1, Xi 27 is O, S, or NR 1 can be made from the compounds 28 3-(2H)-one, 5-bromo-benzothiophene-3-(2H)-one and 5-bromo-indol-3- 29 (2H)-one, or from their appropriately substituted derivatives, substantially in accordance with the reaction steps set forth in Reaction WO 98/25875 WO 9825875PCTIUS97/22581 Scheme 1. These are available in accordance with the chemical literature. For 5-bromo-benzofuran-3 (214)-one see Ellingboe et al J.
Med. Chem. (1992) 35 p1176, and for 5-bromo-benzothiophene-3(2H)one see Pummerel et al Chem. Ber. 42 (1909) 2279. 5-Bromo-indol-3- (211) one can be obtained from 5-bromo-indol-2,3-dione (Patrick et al.
Tet. Letts. (1984) 25 3099) by reduction with LIH 4 followed by oxidation with manganese dioxide (MnO 2 0 <0 9 Br 0 <S a Br Br Na
5-bromo-benzothiophene 3(2H)-one .3-(2H)-one 5-bromo-indol-3- (2H)-one WO 98/25875 WO 9825875PCTIUS97/22581 MeG B MeG PO(OE0 MeG>N, CO 2 Me 2. (I 1 S) MeO>'N CO 2 Me n-BuLi Formula SUC14 e Formula 16 Formula 17 iBA1-H
ix, Formula 18 I PO(OEt 2 IF X=CO 2 Ft n-BuLi Homologs and SDerivatives Formula 19 Reaction Scheme 3 WO 98/25875 PCT/US97/22581 37 1 Reaction Scheme 3 provides an example for the preparation of 2 compounds of the invention where with reference to Formula 1 Y is 3 (CR 3
3 and r is 2, although those skilled in the art will be able 4 to readily modify the steps depicted in this reaction scheme to obtain additional compounds of the invention where r is 1 or 3. The dimethyl 6 acetal of ethyl 4-oxobutyrate is the starting material in accordance with 7 this scheme. The latter compound can be obtained in accordance with 8 the publication Smith et al. J. Am. Chem. Soc. 113 1991 pp 2071 9 2073. The dimethyl acetal of ethyl 4-oxobutyrate is brominated with Nbromosuccinimide, and the resulting dimethyl acetal of 2-bromo-4- 11 oxobutyrate is reacted with triethylphosphite to give the dimethyl acetal 12 of ethyl 2 -diethylphosphoryl-2-oxo-butyrate. The dimethyl acetal of 13 ethyl 2 -diethylphosphoryl-2-oxo-butyrate is reacted in a Homer Emmons 14 type reaction, in the presence of strong base such as n-butyl lithium, with an aldehyde of Formula 15. In Formula 15 R 4 and X 1 are defined 16 as in connection with Formula 1. Therefore, the aldehyde of Formula 17 15 can be an aldehyde derivative of 1-aryl or 1-heteroaryl 1,2,3,4- 18 tetrahydronaphthalene or of a 4-aryl or 4-heteroaryl chrom-3-ene, 4-aryl, 19 4-heteroaryl thiochrom-3-ene, or 4-aryl or 4-heteroaryl 1,2dihydroquinoline. More specific examples for the aldehydes which are 21 used in this reaction scheme are the aldehydes of Formula 5 disclosed 22 in connection with Reaction Scheme 1, and the aldehydes of Formula 12 23 disclosed in connection with Reaction Scheme 2. The product of the 24 Homer Emmons condensation reaction is a pentenoic acid derivative of Formula 16, which is cyclized in the subsequent reaction step to provide 26 an ethyl carboxylate derivative of the aryl or heteroaryl substituted 3,4- 27 dihydroanthracene or aryl or heteroaryl substituted benzo[1,2-g]-chrom- 28 3-ene, benzo[1,2-g]-thiochrom-3-ene and benzo[1,2-g]-1,2- 29 dihydroquinoline compounds shown in Formula 17. The ethyl carboxylate function of the compounds of Formula 17 is reduced with a WO 98/25875 PCT/US97/22581 38 1 suitable reducing agent, such as diisobutyl aluminum hydride (DiBAI- 2 to provide the aryl or heteroaryl substituted 3,4-dihydroanthracene 3 aldehyde, aryl or heteroaryl substituted benzo[1,2-g]-chrom-3-ene 4 aldehyde, benzo[1,2-g]-thiochrom-3-ene and benzo[1,2-g]-1,2s dihydroquinoline aldehyde compounds of Formula 18. The aldehydes 6 of Formula 18 are then reacted in another Homer Emmons reaction 7 with ethyl-diethylphosphono-3-methyl 2(E)butenoate which can be 8 obtained in acordance with the literature procedure of Corey et al. J.
9 Org. Chem. (1974) 39 p821. The product of this last Homer Emmons reaction is the pentadienoic acid derivative of Formula 19 which is 11 within the scope of the present invention. The compounds of Formula 12 19 can be converted into further homologs and derivatives still within 13 the scope of the invention, as described above.
14 1 PP3 16
i7 Xi BuLi
18 Formula 15 Formula 19 X2-Y-A-B, Heck Reaction 21 22
23 O O 'A B SnC4
23 X ON 24XI
Formula 22 Formula 21 26 27 Derivatives and homologs 28 29 Reaction Scheme 4 WO 98/25875 PCT/US97/22581 39 1 Reaction Scheme 4 discloses an alternative synthetic route for 2 preparing the compounds of the invention where, with reference to 3 Formula 1, the Y group is aryl or heteroaryl, as specifically defined in 4 connection with that formula. In accordance with this scheme, the aldehyde derivative of a 1-aryl or 1-heteroaryl 1,2,3,4- 6 tetrahydronaphthalene compound or of a 4-aryl or 4-heteroaryl chrom- 7 3-ene, 4-aryl, 4-heteroaryl thiochrom-3-ene, or 4-aryl or 4-heteroaryl 1,2- 8 dihydroquinoline compound of Formula 15 is reacted with the Wittig 9 reagent 3 -dioxolan-2-yl)ethyl)-triphenylphosphonium bromide in the presence of strong base, such as n-butyl lithium. Specific examples 11 for the aldehydes which are used in this reaction scheme are the 12 aldehydes of Formula 5 disclosed in connection with Reaction Scheme 13 1, and the aldehydes of Formula 12 disclosed in connection with 14 Reaction Scheme 2. The Wittig reagent [2-(1,3-dioxolan-2is yl)ethyl)triphenylphosphonium bromide is commercially available from 16 Aldrich Chemical Company Inc. The product of the Wittig reaction is a 17 disubstituted ethene compound of Formula 20. The aryl or heteroaryl 18 substituent designated is introduced into this molecule in a Heck 19 reaction, utilizing a halogen substituted aryl or heteroaryl compound of the formula X 2 -Y-A-B where X 2 is halogen, preferably bromine or 21 iodine, A and B are defined as in connection with Formula 1, and Y is 22 aryl or heteroaryl as defined in Formula 1. Examples for the reagents 23 of formula X 2 -Y-A-B are ethyl 4-bromobenzoate, ethyl 2- 24 bromopyridine-5-carboxylate, ethyl 2-bromopyridine-6-carboxylate, ethyl 2-bromothiophene-4-carboxylate, ethyl 26 ethyl 2-bromofuran-4-carboxylate, and ethyl 27 The Heck reaction is well known in the art, and is usually conducted in 28 a basic solvent, such as triethylamine, in the presence of a phosphine 29 catalyst (such as tris(2-methylphenyl)phosphine or tri-O-tolylphosphine) and in the presence of palladium(II)acetate catalyst. The product of the WO 98/25875 PCT/US97/22581 1 Heck reaction is a disubstituted ethene compound of Formula 21 which 2 is thereafter ring closed under Friedel Crafts like conditions g. in the 3 presence of SnCl 4 as in the analogous reactions described in Reaction 4 Schemes 1 and 2, to provide the compounds of Formula 22. The compounds of Formula 22 are within the scope of the invention, and 6 can be converted into further compounds of the invention by reactions 7 well known in the art. This is designated symbolically in the reaction 8 scheme by showing conversion into homologs and derivatives.
9 SPECIFIC EXAMPLES 1-(Tol-4-yl)3.4-dihvdro-4,4-dimethyl-7-bromo-naphthalene (Compound 11 B) 12 To a mixture of Mg metal (650mg, 27mmol) in THF (20 mL) was 13 added 4-bromotoluene (5.3g, 31 mmol) in THF (40 mL). The mixture 14 was stirred for 2 hours at ambient temperature and heated to 70 0 C for 30 minutes. After cooling to ambient temperature, 3,4-dihydro-4,4- 16 dimethyl-7-bromo-1(2H)-naphthalenone (Compound A) (2.1g, 8mmol), 17 in THF (5 mL) was added and heated to 70 0 C for 24 hours. The 18 mixture was cooled to ambient temperature and the reaction was 19 quenched by addition of H20. The mixture was diluted with ether:ethylacetate 100mL) and washed with saturated NH 4
21 (15mL), water (10mL) and brine (10mL). The organic layer was dried 22 with MgSO 4 Solvent was removed under reduced pressure to afford 23 the crude product as an oil. The product was dissolved in THF 24 mL). To this solution p-toleune sulfonic acid (pTSA) (35mg) was added and the mixture was refluxed for 16 hours. The mixture was cooled to 26 ambient temperature, diluted with ethylacetate (160 mL), washed with 27 10% NaHCO 3 (20 mL), brine (20 mL), dried with MgSO 4 and the 28 solvent wasremoved by evaporation. Purification by chromatography 29 on silica gel gave the title compound as a white solid.
1 HNMR (CDCIl): 8 1.33 6H), 2.34 J=4.8Hz, 2H), 2.42 3H), WO 98/25875 PCT/US97/22581 41 1 6.00 J=4.8Hz, 1H), 7.17 J=2.1Hz, 1H), 7.20-7.30 5H), 7.34 2 (dd, J=2.1, 8.2Hz, 1H).
3 1-(Tol- 4 -yl) 3 .4-dihydro-4.4-dimethyl-7-naphthaldehyde (Compound C) 4 To a cold (-78 0 stirred solution of 1-(tol-4-yl)3,4-dihydro-4,4s dimethyl-7-bromo-naphthalene (Compound B Ig, 3.2 mmol), in THF 6 (17 mL) was added t-BuLi in pentane (1.7M solution, 3mL, 5.1mmol).
7 After 10 minutes dry dimethylformamide (DMF) (600 mg, 8 mmol) was 8 added and the dry-ice cooling was replaced with ice-water bath. The 9 mixture was gradually warmed to ambient temperature and diluted with ethylacetate (150 mL), washed with water (15 mL). The organic layer 11 was dried with MgSO 4 and solvent was removed under reduced 12 pressure. The crude material was purified by silicagel chromatography to 13 afford the title compound as a white solid.
14 1 HNMR (CDCl 3 8 1.38 6H), 2.39 J=4.9Hz, 2H), 2.43 3H), 6.06 J=4.9Hz, 1H), 7.20-7.30 4H), 7.50-7.60 2H), 7.76 (dd, 16 J=1.8, 8.0Hz, 1H), 9.87 1H).
17 Ethyl 4-[1-(2.2-dimethoxyethyl)-2- (tol-4-yl)3,4-dihydro-4.4-dimethyl- 18 naphthalen-7-yl}-(E)-ethenyl]-benzoate (Compound E) 19 To a cold (-78 0 C) solution of ethyl 4-(diethoxyphosphoryl-3,3dimethoxypropyl)benzoate (Compound D, 350 mg, 0.9 mmol, available 21 in accordance with EPO Application No. 0 210 929 published on 22 February 4, 1987), in THF (9 mL), was added n-BuLi in hexane (1.6M 23 solution, 0.7 mL, 1.1 mmol). The mixture was stirred for 1.5 hours. To 24 this solution 1-(tol- 4 -yl) 3 ,4-dihydro-4,4-dimethyl-7-naphthaldehyde (Compound C, 200 mg, 0.72 mmol), in THF (1 mL) was added and the 26 mixture was gradually warmed to ambient temperature The 27 reaction was quenched by adding water (5 mL), and extracted with ethyl 28 acetate (3 x 25 mL). The organic layer was washed with brine (10 mL), 29 dried with MgSO 4 and the solvent was removed by distillation. The crude material was purified by silicagel chromatography to afford the WO 98/25875 WO 9825875PCTIUS97/22581 42 1 title compound as a colorless oil.
2 1 HNMR (CDC1 3 8 1.37 6H), 1.11 J=7.lHz, 3H), 2.35 (d, 3 J=4.6Hz, 2H), 2.39 3H), 3.03 J=5.9H-z, 2H), 3.13 6H), 4.29 (t, 4 J=5.9Hz, 1H), 4.39 J=7.lHz, 2H), 5.98 J=4.6Hz, 1H), 6.73 (s, 111), 7.13 1H), 7.20 J=8.2Hz, 2H), 7.27 J=8.2Hz, 2H), 7.40 6 (brs, 2H), 7.48 J=8.3Hz, 2H), 8.02 J=8.3Hz, 2H).
7 Ethyl 4-[1 (tol- 4 -vl)-3,4-dihvdro-4,4-dimethvb-anthracen..8vl] -benzoate 8 (Compound 1) 9 To a cold (-50 0 C) solution of ethyl 4-[1-(2,2-dimethoxyethyl)-2- {11(tol- 4 -yl) 3 ,4-dihydro-4,4-dimethylnaphthalen-7yl }-(E)-ethenyl]- 11 benzoate (Compound E, 19 mg, 0.04 mmol), in dichloromethane (3 12 mL), was added SnCl 4 (2mg in 0.1 mL of dicliloromethane). After 13 minutes the reaction was quenched by adding water (2 mL), extracted 14 with ether (60 mL). The organic layer was washed with water (5 mL), brine (5 mL), dried with MgSO 4 and the solvent was removed by 16 distillation. The product was purified by silicagel chromatography to 17 afford the title compound as a white solid.
18 IHNMR (CDC 3 8 1.43 J=7.lHz, 3H), 1.47 6H), 2.42 (d, 19 J=4.9Hz, 2H), 2.45 3H), 4.41 1=7.1Hz, 2H), 6.08 J=4.9H4z, 1H), 7.25 J=8.OHz, 2H), 7.34 d, J=8.OHz, 2H), 7.54 1H), 7.69 21 (dd, J 8.4Hz, 1H), 7.73 J =8.4Hz, 2H), 7.79 1H), 7.87 (d, 22 J=8.4Hz, 1H), 7.90 (brs, 1H), 8.11 J=8.4Hz, 2H).
23 4-[l1(Tol- 4 -vl)-.3,4-.dihydro-.4,4-.dimethyl-.anthracen.8l]j-.benzoic acid 24 (Compound 2) To a degassed solution of ethyl 4-[1(tol-4-yl)3,4-dihydro-4,4-dimethyl- 26 anthracen-8-yl]-benzoate (Compound 1, 35 mg, 0.08 mmol), in THF 27 mL) and MeOH (1.5 mL) was added LiOH (1M solution in water, 0.3 28 mL, 0.3 mmol). The mixture was stirred at ambient temperature for 16 29 hours, diluted with ether (60 mL). The mixture was acidified with HCl to pH 4, the product was isolated as an ether insoluble white solid.
WO 98/25875 WO 9825875PCTIUS97/22581 43 1 1 HNMR (DMSO-D 6 8 1.11 6H), 2.38 3H), 2.39 2 2H), 6.07 J=4.5Hz, 1H), 7.25-7.33 (in, 4H), 7.51 1H), 7.84 (dd, 3 J 6, 8.Hz, 1H), 7.90-8.05 (in, 6H), 8.15 1 H).
4 Methyl-thien-2-yl)3,4-dihydro..4,4.dimethyl.7.bromonaphthalene (Compound
6 To a cold (-78 0 C) solution of 2-methylthiophene (800 mg, 8.1 minol) 7 in THE (10 mL) was added n-BuLi (1.6M solution in hexane, 5 mL).
8 The mixture was stirred for 1.5 hours and transferred to a cold (-78 0
9 flask containing 3,4-dihydro-4,4-dimethyl.7bromo.1 (2H)-naphthalenone (Compound A, 1.63 g, 6.5 mmol), in THE (15 mL). The mixture was 11 gradually warmed to 0 0 C. The reaction mixture was diluted with 12 ether: ethylacetate 80 mL), washed with water (10 mL), brine 13 mL), dried with MgSO 4 .and the solvent was removed by evaporation.
14 The crude material was dissolved in dichioroethane (20 mL) and pTSA (40 mg) was added. The mixture was stirred at ambient temperature for 16 16 hours and at 50 0 C for 4 hours. The reaction mixture was 17 diluted with ether (150 mL), washed with aqueous 10% NaHCO 3 18 mL), brine (10 mL) and dried with MgSO 4 Purification by 19 chromatography on silica gel gave 1.35 g of the title compound as a white solid.
21 1 HNMR (CDCI 3 8 1.26 6H), 2.31 J =4.9Hz, 2H), 2.52 3H), 22 6.15 J=4.9Hz, 1H), 6.72 J=3.3Hz, 1H), 6.83 J=3.3HZ, 1H1), 23 7.21 J=8.3H, 1H), 7.34 (dd, J=2.0, 8.3Hz, 1H), 7.55 J=2.OHz, 24 1H).
1 (5-Methyl-thien-2-vl) 3,4-dihvdro-4,4-dimethyl-7-naphthaldehyde 26 (Compound G) 27 To a cold (-78 0 C) solution of 1-(5-methyl-thien-2-yl)-3,4-dihydro-4,4- 28 dimethyl-7-bromo-naphthalene (Compound F, 1.35 g, 4.1 inmol), in 29 THE (20 mL) was added t-BuLi in pentane (137M solution, 3.5 mL, 5.95 minol). The reaction was stirred for 15 minutes. and DMF (600 mg, 5.8 WO 98/25875 WO 9825875PCTIUS97/22581 44 immol) was added and dry-ice cooling was replaced with ice-water bath.
2 The mixture was stirred at ambient temperature for 4 hours. The 3 reaction mixture was diluted with ether (70 mL) and washed with water 4 (5 mL), brine (5 mL) and dried with MgSO 4 Solvent was removed by distillation. The product was purified by silicagel chromatography to 6 afford the title compound as a colorless oil.
7 1 HNMR (CDCI 3 8 1.35 6H), 2.35 J=4.8Hz, 2H), 2.52 3H), 8 6.20 J=4.8Hz, 1H), 6.73 J:=3.5Hz, 1H), 6.86 J=3.5Hz, 1H), 9 7.52 J=7.9Hz, 1H), 7.77 (dd, J=1.8, 7.9Hz, 1H), 7.94 J=1.8Hz, 1H), 9.93 1H).
11 Ethyl 4-[1 -(2..2-dimethoxvethyl)-2-f 1 -(5-methyl-thien-2-yl)3,4-dihydro- 12 4,4-dimethvl-naphthalen-7-vl }-(E)-ethen- 1-yl]-benzoate (Compound H) 13 To a cold (-78 0 C) solution of ethyl 4-(diethoxyphosphoryl-3,3- 14 dimethoxypropyl)benzoate (Compound D, 1.4 g, 3.6 mmol), in THIF mL) was added n-BuLl (1 .6 M solution in hexane, 2.5 mL, 4 mmol).
16 The mixture was stirred for 20 minutes at -78 0 C and 10 min. at -10 0
17 The reaction mixture was recooled to -78 0 C and 1(5-methyl-thien-2- 18 yl) 3 ,4-dihydro-4,4-dimethyb-7.naphthaldehyde (Compound G, 650 mg, 19 2.3 mmol) in THF (4 mL) was added to it. The mixture was stirred for 2 hours at -10 0 C and diluted with ether (100 mL), washed with brine 21 (10 mL) dried with MgSO 4 and the solvent was removed by distillation 22 to to afford a cis and trans (E and Z) isomeric mixture. Purification by 23 chromatography on silica gel of the crude material afforded the title 24 compound as an oil 90% purity).
IHNMR (CDC1 3 8 1.33 6H), 1.41 J=7.lHz, 3H), 2,32 (d, 26 J=4.9Hz, 2H), 2.49 3H), 3.06 J=5.7Hz, 2H), 3.16 6H), 4.32 (t, 27 J=5.7Hz, 1H), 4.39 J=7.lHz, 2H), 6.13 J=4.9Hz, 111), 6.70 (d, 28 J=3.5Hz, 1H), 6.78 1H), 6.85 J=3.5Hz, 111), 7.37 J=8.OHz, 29 1H), 7.43 (dd, J=1.7, 8.0Hz, 1H), 7.50 J=8.3Hz, 3H), 8.02 (d, J=8.3Hz, 2H).
WO 98/25875 PCT/US97/22581 1 Ethyl 4-[l(5-methyl-thien-2-yl)3,4-dihydro-4,4-dimethvl-anthracen-8-yl]- 2 benzoate (Compound 3) 3 To a cold (-50 0 C) solution of ethyl 4-[1-(2,2-dimethoxyethyl)-2-{1(5- 4 methyl-thien-2-yl)3,4-dihydro-4,4-dimethyl-naphthalen-7-yl}-(E)-ethenyl]benzoate (Compound H, 130 mg, 0.25 mmol), in dichloromethane 6 mL) was added SnC14 (22 mg, in 0.1 mL dichloromethane). After 7 min. the reaction was quenched by adding solid NaHCO 3 (100 mg) 8 followed by aqueous 10% NaHCO 3 (5 mL), and the resulting mixture 9 was extracted with ether (60 mL). The organic layer was washed with water (5 mL), brine (5 mL) dried with MgSO 4 and the solvent was 11 removed by distillation. The product was purified by silicagel 12 chromatography to afford the title compound as a white solid.
13 1 HNMR (CDC1 3 8 1.43 J=7.1Hz, 3H), 1.44 6H), 2.40 (d, 14 J=4.8Hz, 2H), 2.56 3H), 4.41 J=7.1Hz, 2H), 6.25 J=4.8Hz, 1H), 6.77 J=3.4Hz, 1H), 6.96 J=3.4Hz, 1H), 7.71 (dd, J=1.7, e1 8.4Hz, 1H), 7.76 J=8.5Hz, 2H), 7.78 1H), 7.88 J=8.4Hz, 1H), 17 7.95 (brs, 1H), 7.99 (brs, 1H), 8.12 J=8.4Hz, 2H).
18 4 1(5-Methyl-thien-2-l)3,4-dihvdro-4,4-dimethyl-anthracen-8-yl]-benzoic 19 acid (Compound 4) To a stirred solution of ethyl 4-[1-(5-methyl-thien-2-yl)-3,4-dihydro- 21 4 4 -dimethyl-anthracen-8-yl]-benzoate (Compound 3, 33 mg, 0.07 mmol), 22 in THF (2 mL), MeOH (2 mL), was added aqueous LiOH (1M 23 solution, 0.2 mL, 0.2 mmol). After 16 hours, water (2 mL) was added to 24 the reaction mixture, about 50% of the organic solvents were removed by distillation, and the mixture was further diluted the mixture with 26 water (5 mL). The reaction mixture was washed with ether (10 mL) and 27 the aqueous layer was acidified to pH 4 and extracted with ethyl acetate 28 (3 x 20 mL). The combined organic layers were washed water (5 mL), 29 brine (10 mL), dried with MgSO 4 and the solvent was removed by distillation. The product was recrystallized from acetone to obtain the WO 98/25875 WO 9825875PCT/US97/22581 46 title compound as a white solid.
2 1 HNMR (CDCI 3 8 1.44 6H), 2.40 J=4.9Hz, 2H), 2.56 3H), 3 6.24 J=4.9Hz, 1H), 6.79 J=3.4Hz, 11H), 6.96 J=3.4Hz, 1H), 4 7.23 (dd, J= 1.7, 8.4Hz, 1H), 7.79 (brs, 1H), 7.80 J=8.4Hz, 2H), 7.88 J=8.4Hz, 1H), 7.96 1H), 8.01 1H), 8.18 J=8.4Hz, 2H).
6 1-( 6 -Methyl-pyrid-3-l)-3,4-dihydro..4,4-dimethy..7.bromo..naphthalene 7 (Compound 1) 8 To a cold (-78 0 C) solution of 6-methyl-3-bromopyridine (890 mg, 5.2 9 mmol) in THF (15 mL) was added n-BuLi in hexane (1.6M solution, mL, 5.6 mmol) and stirred for 1 hour. This mixture was added to a flask 11 containing 3,4-dihydro-4,4-dimethyl-7-bromo- 1(2H)-naphthalenone 12 (Compound A, 1.35 g, 5.4 mmol), in THF (5 mL) at -78 0 C. The 13 reaction mixture was gradually warmed to ambient temperature and 14 stirred for 16 hours. Thereafter it was diluted with ethyl acetate (100 mL), washed with water (10 mL), brine (10 mL) and dried with MgSO 4 16 Solvent was removed by distillation, the crude material was dissolved in 17 toluene (25 mL) and pTSA (530 mg, 2.8 mmol) was added. The mixture 18 was heated at 90 0 C for 36 hours. Thereafter it was diluted with ethyl 19 acetate (100 mL), washed with 10% NaHCO 3 (2 xlO mL), brine mL), dried with MgSO 4 and the solvent was removed by evaporation.
21 The title compound was obtained by recrystallization from ethyl acetate 22 and hexane mixture 23 1 HNMR (CDCl 3 8 1.31 6H), 2.34 J=4.7Hz, 2H), 2.60 3H), 24 6.02 J=4.7Hz, 1H), 7.05 J=2.lHz, 1H), 7.17 J=7.8Hz, 1H), 7.21 J=8.3Hz, 1H), 7.34 (dd, J=2.1, 8.2H4z, 1H), 7.51 J=2.3, 26 8.3Hz, 1H), 8.46 J=2.3Hz, 1H).
27 Ethyl l-( 6 -methvl-pyid-3-yl)3,4-dihvdro-4.4-dimethyl..7.naphthoate 28 (Compound J) 29 Carbon monoxide gas was bubbled for 5 minutes through a mixture of 1 6 -methyl-pyrid-3-y)3,4-dihydro-4,4dimethyl.7.bromonaphthalene WO 98/25875 PCT/US97/22581 47 1 (Compound J, 250 mg, 0.75 mmol), Et 3 N (5 mL), MeOH (10 mL), 2 DMSO (10 mL), Pd(PPh 3 2 C1 2 (70 mg, 0.1 mmol) and 1,3- 3 bis(diphenylphophino)propane (206mg, 0.5 mmol). The mixture was 4 heated to 50 0 C for 16 hours under a carbon monoxide atmosphere s (carbon monoxide balloon). Thereafter solvent was distilled off, water 6 (15 mL) was added, and the mixture was extracted with ethyl acetate (3 7 x 40 mL). The combined organic layers were washed with water 8 mL), brine (10 mL) dried with MgSO 4 and the solvent was removed by 9 evaporation. The crude material was purified by silicagel column chromatography to afford the title compound as a white solid.
11 1 HNMR (CDC1 3 8 1.33 6H), 2.35 J=4.9Hz, 2H), 2.59 3H), 12 3.80 3H), 6.03 J=4.9Hz, 1H), 7.16 J=8.0Hz, 1H), 7.41 (d, 13 J=8.0Hz, 1H), 7.51 (dd, J=2.2, 8.0Hz, 1H), 7.60 J=1.8Hz, 1H), 7.89 14 (dd, J=1.8, 8.0Hz, 1H), 8.47 J=2.2Hz, 1H).
is 16(6-methyl-pyrid-3-vy)3,4-dihydro-4,4- dimethyl-naphthaldehyde 16 (Compound K) 17 To a cold (-78 0 C) solution of methyl 1-(6-methyl-pyrid-3-yl)3,4- 18 dihydro-4,4-dimethyl-7-naphthoate (Compound J, 200 mg, 0.65 mmol), 19 in dichloromethane (4 mL) was added DiBAl-H in dichloromethane (1M solution, 2 mL, 2 mmol). The mixture was stirred for 2 hours, 21 quenched with aq. KOH solution (100 mg in 2 mL), and a gel 22 precipitate formed. The mixture was transferred to a seperatory funnel, 23 and was extracted with ethyl acetate (3 x 30mL). The combined organic 24 layers were washed with brine (10 mL), dried with MgSO 4 and the solvent was removed by evaporation. The crude product was dissolved 26 in dichloromethane (10 mL), MnO 2 (650 mg, 7.5 mmol) was added and 27 the mixture was stirred for 6 hours. The solid was filtered off, and the 28 solvent was removed to afford the title compound as a white solid.
29 1 HNMR (CDCl 3 8 1.38 6H), 2.41 J=4.7Hz, 2H), 2.63 3H), 6.09 J=4.7Hz, 1H), 7.21 J=8.0Hz, 1H), 7.44 J=1.8Hz, 1H), WO 98/25875 WO 9825875PCTIUS97/22581 48 1 7.51-7.59 (in, 3H), 7.77 (dd, J=1.8, 8.0Hz, 1H), 8.49 J=1.8Hz, 1H), 2 9.86 1H).
3 Ethyl 4-[l1-( 6 -methyl-pvrid-3-vl)-3,4-dihydro.4,4-.dimethyl-anthracen.8.l] 4 benzoate (Compound This compound is prepared in accordance with the procedure 6 described for the preparation of ethyl 4-[1(5-methyl-thien-2-yl)3,4- 7 dihydro-4,4-dimethyl-anthracen-8-yl]pbenzoate (Compound from 1(2- 8 methyI-pyrid-5-yl)3,4-dihydro..44-dimethyl..naphthaldehyde (Compound 9 K) by reaction with ethyl 4-(diethoxyphosphoryl-3,3dimethoxypropyl)benzoate (Compound D) and proceeding through the 11 intermediate ethyl 4-[1-(2,2-dimethoxyethyl)-2-{ 1-(tol-4-yl)3,4-dihydro- 12 4 4 -dimethyl-naphthalen-7-yi}-(E)-ethen-1yl]..benzoate which is cyclized 13 by treatment with SnCl 4 in dichioromethane to give the title compoud.
14 4- [1 6 -methvl-pyrid- 5 vl)-3..4-dihdro.4,4 dim ethyla nthracen8y]benzoic acid (Compound 6) 16 The title compound is obtained by saponification with LiGH of 17 ethyl 4- 1 (tol- 4 -yl) -3,4-d ihydro-4,4- dime thyl-anthracen -benzo ate 18 (Compound 5) in accordance with the procedure described for the 19 preparation of 1(5 -methyl-thien-2-yl) 3,4-dihydro-4,4-dimethyl anthracen-8-yl]-benzoic acid (Compound 4).
21 3 -Methvl-3-(4-bromo-thiophenyl) buyic acid (Compound L) 22 A mixture of 4-bromothiophenol (9.5g, 50 mmol), 3,3-dimethylacrylic 23 acid (5g, 50 inmol) and piperidine were heated (HO 0 C) in a screw cap 24 heavy walled tube covered with teflon cap. The reaction mixture became a thick liquid after 30 minutes of heating. Heating was 26 continued for 23 hours. Then the mixture was cooled to ambient 27 temperature, andsolved in ethyl acetate (200 mL). The mixture was 28 washed with 10% aq. HCI, water (50 mnL), brine (50 mL) and dried with 29 MgSO 4 Solvent was removed and the crude product was recrystallized from hexane to afford the title compound as a colorless solid.
WO 98/25875 PCT/US97/22581 49 1 1HNMR (CDC1 3 8 1.42 6H), 2.55 2H), 7.43 J=8.6Hz, 2H), 2 7.49 J=8.6Hz, 2H).
3 2 2 -Dimethyl-6-bromo-thiochroman-4-one (Compound M) 4 To a solution of 3-methyl-3-(4-bromo-thiophenyl) butyric acid s (Compound L, 9.1g, 33.4 mmol) in benzene (125 mL) was added oxalyl 6 chloride (7.4g, 59 mmol). The mixture was stirred for 5 hours at 7 ambient temperature, and thereafter washed with ice-cold 5% NaOH 8 (100 mL), ice-cold water (2 x 50 mL) and brine (50 mL). The organic 9 layer was dried with MgSO 4 and the solvent was removed by distillation.
The residual colorless oil was dissolved in dichloromethane (50 mL), 11 cooled to 0°C and SnCl 4 (14.7 g, 57 mmol) was added. The mixture 12 was stirred at ambient temperature for 14 hours, and poured into ice.
13 The mixture was extracted with ethyl acetate, washed with 10% NaOH, 14 water, brine, dried with MgSO 4 and the solvent was removed by is distillation. The crude material was purified by silicagel chromatography 16 and after standing at ambient temperature for overnight crystalline 17 product was collected by filtration.
18 1 HNMR (CDCl 3 8 1.46 6H), 2.87 2H), 7.12 J=8.4Hz, 2H), 19 7.50 (dd, J=2.2, 8.4Hz, 1H), 8.22 J=2.2Hz, 1H).
2 2 -Dimethyl-4(tol-4-yl)-6-bromo-thiochrom-3-ene (Compound N) 21 To a cold (-78 0 C) solution of 4-bromotoluene (720 mg, 4.2 mmol) in 22 THF (8 mL) was added t-BuLi in pentane (1.7M, 0.5 mL, 0.85 mmol).
23 The mixture was warmed to ambient temperature over 30 minutes with 24 stirring. This mixture was added to a flask containing 2,2-dimethyl-6bromo-thiochroman-4-one (Compound M, 140 mg, 0.4 mmol) and THF 26 (2 mL). and stirred for 16 hours at ambient temperature. The reaction 27 was quenched by adding aq. NH 4 C1, and the resulting mixture was 28 extracted with ethylacetate, washed with brine, dried and the solvent was 29 removed by evaporation. The product was isolated by chromatography on silica gel. The material was dissolved in dichloromethane (5 mL) WO 98/25875 PCT/US97/22581 1 and pTSA (5 mg) was added and heated to 50 0 C for 3 hours. The 2 misture was diluted with ethylacetate (20 mL), washed with 3 NaHCO 3 (5 mL), brine (5 mL), dried with MgSO 4 and the solvent was 4 removed by evaporation to afford the title compound as an oil.
s 1 HNMR (CDC1 3 8 1.46 6H), 2.40 3H), 5.84 1H), 7.12-7.29 6 7H).
7 2 ,2-Dimethyl-4(tol-4-yl)-thiochrom-3-en-6-al (Compound O) 8 To a cold (-78oC) solution of 9 2 2 -dimethyl-4(tol-4-yl)-6-bromo-thiochrom-3-ene (Compound N, 280 mg, 0.81 mmol) in THF (5 mL) was added n-BuLi in hexane (1.6 M 11 solution, 0.66 mL). The mixture was gradually warmed to -10 0 C over 12 25 min. and recooled to -78 0 C. To this solution was added DMF 13 mg, 1.1 mmol) and stirred at ambient temperature for 5 hours. The 14 reaction was quenched by adding water (10 mL), ethyl acetate (100 mL), and the organic layer was washed with brine (10 mL), dried and 16 the solvent removed by distillation. The crude material was used in the 17 next reaction without further purification.
18 Ethyl 4 2 2 -dimethyl-4-(tol-4-vl)-6.7-benzothiochrom-3-en-7-vl]benzoate 19 (Compound 7) To a cold solution of ethyl 4-(diethoxyphosphoryl-3,3- 21 dimethoxypropyl)benzoate (Compound D, 536 mg, 1.4 mmol) in THF 22 (5 mL) was added n-BuLi in hexane (1.6 M solution, 1.2 mL) and 23 stirred for 1 hour between -78 0 C and -10°C. The mixture was cooled to 24 -78 0 C and 2,2-dimethyl-4(tol-4-yl)-thiochrom-3-en-6-al (Compound O, as obtained in the previously described reaction) in THF (1 mL) was 26 added to it. The reaction mixture was stirred at ambient temperature for 27 1 hour and diluted with ethyl acetate (60 mL), washed with brine 28 mL), dried and the solvent was removed by evaporation. The crude 29 material was purified by column chromatography to afford the E and Z isomers as a mixture. The mixture of E and Z isomers was dissolved in WO 98/25875 PCT/US97/22581 51 1 dichloromethane (4 mL) and cooled to -78 0 C. To the cold solution was 2 added SnCl4 (110 mg, 0.42 mmol) in dichloromethane (1 mL). The 3 reaction mixture was stirred between -78°C and -30°C for 30 minutes 4 and then quenched with ethanol (0.2 mL), diluted with ethyl acetate mL), washed with brine, dried and the solvent was removed by 6 distillation. The crude material was purified by column chromatography 7 to obtain the title compound as a white solid.
8 'HNMR (CDC13): d 1.43 J=7.2 Hz, 3H), 1.53 6H), 2.44 3H), 9 4.41 J=7.2 Hz, 2H), 6.02 1H), 7.21-7.31 4H), 7.59 1H), 7.69-7.75 3H), 7.80 J=8.5 Hz, 1H), 7.88 2H), 8.11 J=8.3 11 Hz, 2H).
12 4 2 2 -dimethvl-4-(tol-4-yl)-6.7-benzothiochrom-3-en-7-yl]benzoic acid 13 (Compound 8) 14 To an argon purged solution of ethyl 4-[2,2-dimethyl-4-(tol-4-yl)- 6 ,7-benzothiochrom-3-en-7-yl]benzoate (Compound 7, 12 mg, 0.03 16 mmol), THF (2 mL) and MeOH (1 mL) was added LiOH in water (1M 17 solution, 0.2 mL) and purged (with argon) for 2 minutes. The mixture 18 was stirred for 16 hours at ambeint temperature. The reaction mixture 19 was acidified with 10% hydrochloric acid to pH 4, extracted with ethyl acetate (35 mL), washed with brine, dried and the solvent was removed 21 by distillation. The title compound was obtained as an off white solid.
22 'HNMR (Acetone-D6): d 1.50 6H), 2.39 3H), 6.08 1H), 7.26 (s, 23 4H), 7.84-7.96 (m 5H), 8.12 J=8.3 Hz, 3H).
24 2 2 -Dimethyl-4(tol-4-yl)-6-bromo-chrom-3-ene (Compound P) To cold (-78 0 C) solution of 4-bromotoluene (1.71 g, 10 mmol) in 26 THF (16 mL) was added t-BuLi in pentane (1.7M, 3 mL). The mixture 27 was warmed to ambient temperature and stirred for 15 minutes and 28 then recooled to -78 0 C. To this solution, 2,2-dimethyl-6-bromo- 29 chroman-4-one (750 mg, 3 mmol) in THF (4 mL) was added and stirred for 30 minutes. 2,2-Dimethyl-6-bromo-chroman-4-one is available in WO 98/25875 PCT/US97/22581 52 1 accordance with the procedure of Bickle et al. J. Med. Chem. 1990 33 2 p3028. The reaction was quenched with water (5 mL), extracted with 3 ethyl acetate (10 mL), washed with brine, dried and the solvent was 4 removed by evaporation. Chromatography of the crude mixture afforded 2 2 -dimethyl-4-tolyl-4-hydoxy-6-bromo-chroman an oil. This 6 product was dissolved in dichloromethane (25 mL), and pTSA (25 mg) 7 was added and the mixture stirred for 12 hours. The mixture was then 8 diluted with ethyl acetate (125 mL), washed with 10% NaHCO 3 9 mL), brine, dried and the solvent was removed by evaporation to afford the title compound as a yellow oil.
11 1 HNMR (CDC1 3 8 1.48 6H), 2.41 3H), 5.61 1H), 6.76 (d, 12 J=8.3 Hz, 1H), 7.11 J=2.4 Hz, 1H), 7.22 4H), 7.26 (dd, J=2.4, 13 8.3 Hz, 1H).
14 2 2 -Dimethyl-4(tol-4-vl)-chrom-3-en-6-al (Compound Q) To a cold (-78 0 C) solution of 2,2-dimethyl-4(tol-4-yl)-6-bromo- 16 chrom-3-ene (Compound P, 480 mg, 1.45 mmol) in THF (10 mL), was 17 added t-BuLi in pentane (1.7M solution, 1.1 mL) and the mixture was 18 stirred for 30 minutes. DMF (200 mg, 2.9 mmol) was added, the 19 mixture was warmed to ambient temperature and stirred for 3 hours.
The reaction was diluted with ethyl acetate (150 mL), washed with brine 21 (10 mL), dried and the solvent was removed by evaporation.
22 Purification by chromatography on silica gel column gave the title 23 compound as a colorless oil.
24 1 HNMR (CDC1 3 8 1.54 6H), 2.41 3H), 5.66 1H), 6.98 (d, J=8.3 Hz, 1H), 7.24 4H), 7.57 J=2.0 Hz, 1H), 7.71 (dd, 26 8.3 Hz, 1H), 9.77 1H).
27 Ethvl-4-[2,2-dimethyl-4-(tol-4-vl)-benzo[1,2-g]-chrom-3-en-7-vl]benzoate 28 (Compound 9) 29 To a cold (-78 0 C) solution of ethyl 4-(diethoxyphosphoryl-3,3dimethoxypropyl)benzoate (Compound D, 1.4 g, 3.6 mmol) in THF (9 WO 98/25875 PCT/US97/22581 53 1 mL) was added n-BuLi in hexane (1.6 M solution, 2.8 mL). The mixture 2 was gradually warmed to ambient temperature over 30 minutes and 3 stirred for 5 minutes. To this mixture was added 2,2-dimethyl-4(tol-4-yl)- 4 chrom-3-en-6-al (Compound Q, 260 mg, 0.93 mmol) in THF (1 mL) at ambient temperature and the mixture was stirred for 5 hours. The 6 reaction mixture was diluted with ethyl acetate (100 mL) and washed 7 with brine (10 mL) dried and the solvent was removed by evaporation.
8 The residual material was subjected to flash chromatography on 9 silicagel to obtain the E and Z olefinic compounds, which were dissolved in dichloromethane (5 mL) and cooled to -50 0 C. A solution 11 of SnC14 in dichloromethane (150 mg in 0.7 mL) was added to the 12 olefinic compounds. The reaction mixture was gradually warmed to 13 10 0 C over 3hours and then quenched with methanol and water. The 14 reaction mixture was diluted with ethyl acetate (100 mL). The organic layer was washed with brine and dried. Solvent was removed under 16 reduced pressure and the residue purified by chromatography on 17 silicagel to afford the title compound as a white solid.
18 1 HNMR (CDC1 3 8 1.43 J=7.1 Hz, 3H), 1.55 6H), 2.45 3H), 19 4.41 J=7.1 Hz, 2H), 5.85 1H), 7.24-7.38 5H), 7.53 1H), 7.65-7.78 4H), 7.88 1H), 8.11 J=8.5 Hz, 2H).
21 4 2 2 -Dimethyl-4-(tol-4-vl)-benzo(1,2-g)-chrom-3-en-7vl]benzoic acid 22 (Compound 23 By following the procedure employed for the preparation of 4-[1(5- 24 methyl-thien-2-yl)3,4-dihydro-4,4-dimethyl-anthracen-8-yl]-benzoic acid (Compound ethyl 4-[2,2-dimethyl-4-(tol-4-yl)-benzo(1,2-g)-chrom- 26 3-en-7-yl]benzoate (Compound 9, 10 mg, 0.02 mmol), was converted 27 into the title compound using LiOH in water (0.2 mL, 0.2mmol). The 28 title compound was obtained as an off white solid.
29 'HNMR (Acetone-D6) d 1.52 6H), 2.41 3H), 5.96 1H), 7.27-7.38 4H), 7.60 1H), 7.78-7.86 3H), 7.90 J=8.2 Hz, WO 98/25875 PCT/US97/22581 54 1 2H), 8.10 J=8.2 Hz, 2H), 8.11 1H).
2 2,2-Dimethyl-4(5-methvl-thien-2-yl)-6-bromo-chrom-3-ene (Compound 3 R) 4 To a cold (-78 0 C) solution of 2-methylthiophene (820 mg, 8.3 mmol) s in THF (16 mL) was added n-BuLi in hexane (1.6M, 4.4 mL, 8.5 mmol).
6 The mixture was warmed to ambient temperature and stirred for 7 minutes. This solution was added to a flask containing cold (-78 0
8 solution of 2,2-dimethyl-6-bromo-chroman-4-one (1.08 g, 4.2 mmol) in 9 THF (4 mL). The mixture was stirred and allowed to gradually warm to ambient temperature over 8 hours, and then stirred for an additional 4 11 hours at ambient temperature. The mixture was diluted with ethyl 12 acetate (200 mL), washed with 10% HC1, brine (20 mL), dried and the 13 solvent was removed by evaporation. The product was purified by 14 chromatography on a silica gel column to afford the title compound as a colorless oil.
16 1 HNMR (CDCl 3 8 1.46 6H), 2.52 3H), 5.75 1H), 6.73 (brs, 17 1H), 6.76 J=8.4 Hz, 1H), 6.88 J=2.5 Hz, 1H), 7.26 (dd, 18 8.4 Hz, 1H), 7.48 J=2.4 Hz, 1H).
19 2 2 -Dimethvl-4(5-methvl-thien-2-vl)-chrom-3-en-6-al (Compound S) To a cold (-78 0 C) solution of 2,2-dimethyl-4(5-methyl-thien-2-yl)-6- 21 bromo-chrom-3-ene (Compound R, 1.2 g, 3.6 mmol) in THF (10 mL), 22 was added 23 t-BuLi in pentane (1.7M solution, 2.3 mL). After 30 minutes, DMF 24 (465 mg, 5 mmol) was added and the mixture was allowed to warm to ambient temperature and stirred for 3 hours. The mixture was diluted 26 with ethyl acetate (150 mL), washed with brine (10 mL), dried and the 27 solvent was removed by evaporation. Purification by chromatography 28 on silica gel column gave the title compound as a colorless oil.
29 1 HNMR (CDC1 3 8 1.51 6H), 2.52 3H), 5.80 1H), 6.75 (d, J=2.7 Hz, 1H), 6.91 J=2.7 Hz, 1H), 6.97 J=8.3 Hz, 1H), 7.73 WO 98/25875 PCT/US97/22581 1 (dd, J=2.0, 8.3 Hz, 1H), 7.94 J=2.0 Hz, 1H), 9.83 1H).
2 Ethvl-4-[2,2-dimethyl-4-(5-methvl-thien-2-yl)-benzo[1,2-g]-chrom-3-en-7- 3 yl]benzoate (Compound 11) 4 To a cold (-78 0 C) solution of ethyl 4-(diethoxyphosphoryl-3,3s dimethoxypropyl)benzoate (Compound D, 690 mg, 1.75 mmol) in THF 6 (8 mL) was added n-BuLi in hexane (1.6 M solution, 1.1 mL). The 7 mixture was gradually warmed to ambient temperature over 30 min and 8 stirred for 5 minutes. The mixture was recooled to -78 0 C and 2,2- 9 dimethyl-4(5-methyl-thien-2-yl)-chrom-3-en-6-al (Compound S, 300 mg, 1.1 mmol) in THF (1 mL) was added to the reaction mixture. The 11 mixture was stirred at ambient temperature for 2 hours. The reaction 12 mixture was diluted with ethyl acetate (100 mL) and washed with brine 13 (10 mL) dried and the solvent was removed by evaporation. The 14 material was subjected to flash chromatography on silica gel to obtain is the E and Z olefinic compounds, which were dissolved in 16 dichloromethane (5 mL) and cooled to -78 0 C. A solution of SnC1 4 in 17 dichloromethane (52 mg in 0.2 mL) was added to the olefinic 18 compounds. The resulting mixture was stirred for 30 minutes, quenched 19 with methanol, water and diluted with ethyl acetate (100 mL). The organic layer was washed with brine and dried. Solvent was removed 21 under reduced pressure and purified by silicagel chromatography to 22 afford the title compound as a white solid.
23 1 HNMR (CDCl 3 8 1.43 J=7.1 Hz, 3H), 1.53 6H), 2.56 3H), 24 4.41 J=7.1 Hz, 2H), 5.99 1H), 6.79 J=3.5 Hz, 1H), 7.00 (d, J=3.5 Hz, 1H), 7.29 1H), 7.68 (dd, J=1.8, 8.5 Hz, 1H), 7.72-7.79 (m, 26 3H), 7.93 1H), 7.97 1H), 8.14 J=8.5 Hz, 2H).
27 4 2 2 -Dimethyl-4-(5-methvl-thien-2-vl)-benzo[1.2-g]-chrom-3-en-7- 28 vl]benzoic acid (Compound 12) 29 To a solution of ethyl-4-[2,2-dimethyl-4-(5-methyl-thien-2-yl)benzo[1, 2 -g]-chrom-3-en-7-yl]benzoate (Compound 11, 18 mg, 0.03 WO 98/25875 PCT/US97/22581 56 1 mmol) in methanol (0.5 mL) and THF (1 mL), was added LiOH in 2 water (1M solution, 0.3 mL). The reaction mixture was stirred for 3 hours, the solvent was removed under reduced pressure, the residue 4 dissolved in water (5 mL), washed with ether (10 mL) and the aqueous s layer was acidified to PH 5. The aqueous layer was extracted with ethyl 6 acetate (3 x 20 mL). The combined organic layers were washed with 7 brine, dried, and the solvent was removed under reduced pressure to 8 afford the title compound as a pale yellow solid.
9 1 HNMR (CH 3
3 8 1.50 6H), 2.52 3H), 6.11 1H), 6.85 (brs, 1H), 7.07 J=3.3 Hz, 1H), 7.31 1H), 7.80-7.90 2H), 7.91 11 J=8.4, 2H), 8.01 1H), 8.12 J=8.4 Hz, 2H), 8.19 1H).
12 2, 2 -Dimethyl-4(2-methvl-thien-5-yl)-6-bromo-thiochrom-3-ene 13 (Compound T) 14 To a cold (-78 0 C) solution of 2-methylthiophene (1.2 g, 12.2 mmol) in THF (8 mL) was added n-BuLi in hexane (1.6M, 8.5 mL). The 16 mixture was warmed to ambient temperature over 30 minutes. with 17 stirring. The mixture was recooled to -78 0 C and a solution of 18 2,2-dimethyl-6-bromo-thiochroman-4-one (Compound M, 1.4 g, 5.2 19 mmol) in THF (10 mL) was added. The mixture was stirred for 16 hours at ambient temperature. Then the reaction mixture was diluted 21 with ether (125 mL), washed with water (10 mL), brine (10 mL) dried 22 and the solvent was removed by evaporation. The product was 23 seperated by column chromatography and was dissolved in 24 dichloromethane (5 mL). To this solution p-TSA (5 mg) was added and the mixture was stirred at ambient temperature for 5 min. The reaction 26 was quenched with 10% NaHCO 3 (3 mL), washed with brine (5 mL), 27 dried and the solvent was removed by distillation. The residual crude 28 material was purified by column chromatography to obtain the title 29 compound as a pale yellow oil.
'HNMR (CDC13): d 1.44 6H), 2.51 3H), 6.00 1H), 6.72 (d, WO 98/25875 PCT/US97/22581 57 1 J=1.1 Hz, 1H), 6.79 J=1.1 Hz, 1H), 7.23 J=8.2 Hz, 1H), 7.29 2 (dd, J=2.1, 8.2 Hz, 1H), 7.58 J=2.1 Hz, 1H).
3 2 2 -Dimethyl-4(2-methvl-thien-5-yl)-thiochrom-3-en-6-al (Compound U) 4 To a cold (-78 0 C) solution of 2,2-dimethyl-4(2-methyl-thien-5-yl)s 6-bromo-thiochrom-3-ene (Compound T, 430 mg, 1.2 mmol) in THF 6 (12 mL) was added n-BuLi in hexane (1.6 M solution, 1 mL). The 7 mixture was gradually warmed to ambient temperature over 1 hour and 8 recooled to -78 0 C. To this solution was added DMF (220 mg, 3 mmol) 9 and the mixture was stirred at ambient temperature for 16 hours. The reaction was quenched by adding water (10 mL) and ethy lacetate (100 11 mL). The organic layer was washed with brine (10 mL), dried and the 12 solvent was removed by distillation to obtain the title compound as a 13 pale yellow oil.
14 1HNMR (CDC13): d 1.47 6H), 2.51 3H), 6.03 1H), 6.72 (d, J=2.5 Hz, 1H), 6.80 J=2.5 Hz, 1H), 7.49 J=8.1 Hz, 1H), 7.68 16 (dd, J=1.7, 8.1 Hz, 1H), 7.95 J=1.7 Hz, 1H), 9.88 1H).
17 Ethyl is 4 2 2 -dimethvl-4-(2-methyl-thien-5-yl)-6,7-benzothiochrom-3-en-7-vl]ben 19 zoate (Compound 13) To a cold (-78 0 C) solution of ethyl 4-(diethoxyphosphoryl-3,3- 21 dimethoxypropyl)benzoate (Compound D, 500 mg, 1.29 mmol) in THF 22 (2.5 mL) was added freshly prepared lithium diisopropylamide in 23 THF(1.5 mmol). The mixture was allowed to warm to -5 0 C over a 24 period of 1 hour and 40 minutes. The reaction mixture was recooled to -78 0 C and 2,2-dimethyl-4(2-methyl-thien-5-yl)-thiochrom-3-en-6-al 26 (Compound U, 180 mg, 0.58 mmol) in THF (2 mL) was added. The 27 reaction mixture was gradually warmed to -10 0 C over 2hours. Then the 28 reaction was quenched by adding water (5 mL) and ethyl acetate 29 mL). The organic layer was washed with brine 10 mL) dried and the solvent was removed by distillation. The product E and Z isomers WO 98/25875 PCT/US97/22581 58 1 were isolated by column chromatography. The required E (minor) 2 isomer (45 mg) was dissolved in dichloromethane (5 mL) and cooled to 3 -78 0 C. To this solution SnCI 4 (110 mg, 0.42 mmol) in dichloromethane 4 (1 mL) was added dropwise, the reaction mixture was gradually warmed to -30 0 C over 30 min. The reaction was quenched by adding ethanol 6 (0.5 mL), water (5 mL) and ethyl acetate (75 mL). The organic layer 7 was washed with brine (10 mL), dried and the solvent was removed by a distillation The title compound was isolated as a white solid after 9 column chromatography.
'HNMR (CDCI 3 d 1.43 J=7.1 Hz, 3H), 1.55 6H), 2.55 3H), 11 4.42 J=7.1 HZ, 2H), 6.19 1H), 6.75 J=1.9 Hz, 1H), 6.90 (d, 12 J=1.9 Hz, 1H), 7.70-7.85 4H), 7.87 1H), 7.97 1H), 8.00 (s, 13 1H), 8.12 J=8.4 Hz, 2H).
14 4 2 2 -Dimethyl-4-(2-methvl-thien-5-vl)-benzo(1,2-g)-thiochrom-3-en-7-vy 1is benzoic acid (Compound 14) 16 To a degassed solution of ethyl 4-[2,2-dimethyl-4-(2-methyl-thien-5- 17 yl)-benzo(1,2-g)-thiochrom-3-en-7--yl]benzoate (Compound 13, 28 mg, 18 0.06 mmol), in THF (2 mL) and MeOH (1 mL) was added LiOH (1M 19 solution in water, 0.2 mL) and the mixture was stirred for 16 hours.
The reaction was acidified to pH 4 and extracted with ethyl acetate 21 mL). The organic layer was washed with brine, dried and the solvent 22 was removed to afford the title compound as a pale yellow solid.
23 1 HNMR (CDClI) d 1.52 6H), 2.55 3H), 6.19 1H), 6.74 (d, 24 J=1.9 Hz, 1H), 6.90 J=1.9 Hz, 1H), 7.71-7.85 4H), 7.88 1H), 7.97 1H), 8.00 1H), 8.12 J=8.4 Hz, 2H).
58A- Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.
*i i'.
1. A compound of the formula (R)n (R2)o X j- Y(Ry2A -A-B wherein X, is 2 2 -NRi-, -C(RI) 2 or RI is independently H or alkyl of 1 to 6 carbons or cycloalkyl of 3 to 6 carbons; R 2 is optional and is defined as lower alkyl of 1 to 6 carbons or cycloalkyl of 3 to 6 carbons, F, Cl, Br, I, CF 3 fluoro substituted alkyl of 1 to 6 carbons or fluoro substituted cycloalkyl of 3 to 6 carbons, OH, SH, alkoxy of 1 to 6 carbons, or alkylthio of 1 to 6 carbons; Sm is an integer between 0 and 4; n is an integer between 0 and 2; So is an integer between 0 and 3; S:R 3 is hydrogen, lower alkyl of 1 to 6 carbons or cycloalkyl of 3 to 6 carbons, F, Cl, Br or I; R 4 is (Rs)p-phenyl, (Rs)p-naphthyl, or (R 5 )p-heteroaryl where the heteroaryl group is 5-membered or 6-membered and has 1 to 3 heteroatoms selected from the group consisting of O, S and N; p is an integer having the values of 0 Rs is optional and is defined as independently F, Cl, Br, I, NO 2 N(Rs) 2 N(Rs)COR, NRs,CON(R8) 2 OH, OCOR 8 ORs, CN, COOH, COORs an alkyl group having 1 to 10 carbons or cycloalkyl of 3 to 10 carbons, fluoro substituted alkyl group having 1 to 10 carbons or fluoro substituted cycloalkyl of 3 to carbons, an alkenyl group having 2 to 10 carbons and 1 to 3 double bonds or a cycloalkenyl group having 3 to 10 carbons and 1 to 3 double bonds, alkynyl group having 2 to 10 carbons and 1 to 3 triple bonds, or a (trialkyl)silyl or (trialkyl)silyloxy group where the alkyl groups independently have 1 to 6 carbons or cycloalkyl of 3 to 6 carbons; SY is a phenyl or naphthyl group, or heteroaryl selected from a group 4 WO 98/25875 PCT/US97/22581 consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, imidazolyl and pyrrazolyl, said phenyl, naphthyl and heteroaryl groups being optionally substituted with one or two R 2 groups, or Y is -(CR 3 CR 3 r is an integer between 1 and 3; A is (CH 2 )q where q is 0-5, lower branched chain alkyl having
3-6 carbons, cycloalkyl having 3-6 carbons, alkenyl having 2-6 carbons and 1 or 2 double bonds, alkynyl having 2-6 carbons and 1 or 2 triple bonds, with the proviso that when Y is -(CR 3 CR 3 then A is (CH 2 )q and q is 0; B is hydrogen, COOH or a pharmaceutically acceptable salt thereof, COOR 8 CONRRi 0 -CH 2 OH, CH 2 CH 2 0COR 1 CHO, CH(ORU) 2 CHOR 3 O, -COR 7 CR,(OR2) 2 CR 7 ORO 3 0, or Si(Cl-6alkyl) 3 where R 7 is an alkyl, cycloalkyl or alkenyl group containing 1 to carbons, R, is an alkyl group of 1 to 10 carbons or (trimethylsilyl)alkyl where the alkyl group has 1 to 10 carbons, or a cycloalkyl group of 5 to carbons, or R, is phenyl or lower alkylphenyl, R 9 and R 10 independently are hydrogen, an alkyl group of 1 to 10 carbons, or a cycloalkyl group of 5-10 carbons, or phenyl or lower alkylphenyl, Rn, is lower alkyl, phenyl or lower alkylphenyl, R, 2 is lower alkyl, and R 13 is divalent alkyl radical of 2-5 carbons. 2. A compound of Claim 1 where Y is phenyl or naphthyl. 3. A compound of Claim 1 where Y is selected from pyridyl, fury and thienyl.
4. A compound of Claim 1 where Y is -(CR 3 CR 3 A compound of Claim 1 where X 1 is -C(R 1 2 C(Ri),
6. A compound of Claim 1 where X, is -C(Ri) 2
7. A compound of Claim 1 where X, is -C(RI) 2
8. A compound of Claim 1 where X, is 2 -NRi-.
9. A compound of Claim 1 where A is (CH2,) and B is COOH or 1 61 a pharmaceutically acceptable salt thereof, COOR,, or CONR,Rio. A compound of Claim 5 where Y is phenyl or naphthyl.
11. A compound of Claim 10 where R, is methyl.
12. A compound of Claim 2 where X, is 2 2 or -C(R) 2
13. A compound of Claim 12 where Ri is methyl.
14. A compound of the formula R2 SA-B R3* R where Ri is independently H or alkyl of 1 to 6 carbons or cycloalkyl of 3 to 6 carbons; R 2 is optional and is defined as lower alkyl of 1 to 6 carbons, or cycloalkyl of 3 to 6 carbons, F, Cl, Br, I, CF 3 fluoro substituted alkyl of 1 to 6 carbons or fluoro substituted cycloalkyl of 3 to 6 carbons, OH, SH, alkoxy of 1 to 6 carbons, or Salkylthio of 1 to 6 carbons; n is an integer between 0 and 2; o is an integer between 0 and 3; R 3 is hydrogen, lower alkyl of 1 to 6 carbons or cycloalkyl of 3 to 6 carbons, F, Cl, Br or I; R4 is (Rs)p-phenyl, (Rs)p-naphthyl, or (Rs)p-heteroaryl where the heteroaryl group is pyridyl, thienyl, furyl or thiazolyl; P is an integer having the values of 0 R s is optional and is defined as independently F, Cl, Br, I, No 2 N(Rs) 2 N(R)CORs, NRsCON(R 8 2 OH, OCORs, ORs, CN, COOH, COORs an alkyl group having 1 to 10 carbons or cycloalkyl of 3 to 10 carbons, or fluoro substituted alkyl group having 1 to 10 carbons or cycloalkyl of 3 to 10 carbons, or fluoro Y substituted alkyl group 1 to 10 carbons or fluoro substituted cycloalkyl of 3 to 1 y carbons; 61A A ~S (CH2)q where q is 0-5, lower branched chain alkyl having 3-6 carbons, cycloalkyl having 3-6 carbons, alkenyl having 2-6 carbons and 1 or 2 double bonds, alkenyl having 2-6 carbons and 1 or 2 triple bonds, a a a. a.. a a .aa a a a. a *a.a a. p 9 9 *aaa 9 9 a 9a a. a a a a. a. .a a 1. 1. WO 98/25875 PCT/US97/22581 62 1 and 2 B is hydrogen, COOH or a pharmaceutically acceptable salt thereof, 3 COOR 8 CONR, 9 -CHO2H, CH 2 OR 1 CH 2 0COR 1 CHO, 4 CH(OR2) 2 CHOR 1 3 O, -COR,, CR 7 (OR,) 2 CR 7 OR 3 0O, or Si(C,.6alkyl) 3 s where R 7 is an alkyl, cycloalkyl or alkenyl group containing 1 to 6 carbons, R 8 is an alkyl group of 1 to 10 carbons or (trimethylsilyl)alkyl 7 where the alkyl group has 1 to 10 carbons, or a cycloalkyl group of 5 to a 10 carbons, or R, is phenyl or lower alkylphenyl, R, and Rio 9 independently are hydrogen, an alkyl group of 1 to 10 carbons, or a cycloalkyl group of 5-10 carbons, or phenyl or lower alkylphenyl, R 1 is 11 lower alkyl, phenyl or lower alkylphenyl, R 2 is lower alkyl, and R 13 is 12 divalent alkyl radical of 2-5 carbons. 13 15. A compound of Claim 14 where RI is H, there is no optional 14 R 2 R3, is H, A is (CH 2 )q and q is 0, B is COOH or a pharmaceutically acceptable salt thereof, COORs, or CONR 9 ,Ri. 16 16. A compound of Claim 15 where R 4 is 4-methylphenyl. 17 17. A compound of Claim 16 where the phenyl ring is 1,4 (para) 18 substituted by the A-B and tricyclic groups, and where B is COOH or a 19 pharmaceutically acceptable salt thereof, or COOR 8 where R 8 is methyl or ethyl. 21 18. A compound of Claim 15 where R 4 is 6-methyl(3-pyridyl). 22 19. A compound of Claim 18 where the phenyl ring is 1,4 (para) 23 substituted by the A-B and tricyclic groups, and where B is COOH or a 24 pharmaceutically acceptable salt thereof, or COOR, where R 8 is methyl or ethyl. 26 20. A compound of Claim 15 where R4 is 5-methyl(2-thienyl). 27 21. A compound of Claim 20 where the phenyl ring is 1,4 (para) 28 substituted by the A-B and tricyclic groups, and where B is COOH or a 29 pharmaceutically acceptable salt thereof, or COOR where R, is methyl or ethyl. 63
22. A compound of the formula R2 2)n A B R3 X (R)o where Xi is O or S; R 2 is optional and is defined as lower alkyl of 1 to 6 carbons or cycloalkyl of 3 to 6 carbons, F, Cl, Br, I, CF 3 fluoro substituted alkyl of 1 to 6 carbons or fluoro substituted cycloalalkyl of 3 to 6 carbons, OH, SH, alkoxy of 1 to 6 carbons, or alkylthio of 1 to 6 carbons; n is an integer between 0 and 2; o is an integer between 0 and 3; R 3 is hydrogen, lower alkyl of 1 to 6 carbons or cycloalkyl of 3 to 6 carbons, F, Cl, Br, or I; R 4 is (Rs)p-phenyl, (R 5 )p-naphthyl, or (Rs)p-heteroaryl where the heteroaryl group is pyridyl, thienyl, furyl or thiazolyl; p is an integer having the values of 0 Rs is optional and is defined as independently F, Cl, Br, I, NO 2 N(R 8 2 N(Rs)CORs, NRsCON(Rs) 2 OH, OCORs ORs, CN, COOH, COORs an alkyl group having 1 to 10 carbons or cycloalkyl of 3 to 10 carbons, or fluoro substituted alkyl group having 1 to 10 carbons or fluoro substituted cycloalkyl of 3 to Scarbons; A is (CH2)q where q is 0-5, lower branched chain alkyl having 3-6 carbons, cycloalkyl having 3-6 carbons, alkenyl having 2-6 carbons and 1 or 2 double bonds, alkynyl having 2-6 carbons and 1 or 2 triple bonds, and 63A B is hydrogen, COOH or a pharmaceutically acceptable salt thereof, COOR 8 CONR 9 R 10 -CH 2 OH, CH 2 0R 11 CH 2 OCOR 11 CHO, CH(OR~) 2 CHOR 13 O, -COR,, CR,(ORIZ) 2 CR 7 0R 13 0, or Si(C 1 6 alkyl) 3 where R, is an alkyl, cycloalkyl or alkenyl group containing 1 to carbons, R 8 is an alkyl group of 1 to 10 carbons or (trimethylsilyl)alkYl where the alkyl group has 1 to 10 carbons, or a cycloalkyl group of 5 to I'. 6* S S *0 S. S S. S S S.. *.st S S S S S S. S *5 55 S WO 98/25875 PCT/US97/22581 64 1 10 carbons, or R, is phenyl or lower alkylphenyl, R, and Ro 1 2 independently are hydrogen, an alkyl group of 1 to 10 carbons, or a 3 cycloalkyl group of 5-10 carbons, or phenyl or lower alkylphenyl, R 1 is 4 lower alkyl, phenyl or lower alkylphenyl, R. is lower alkyl, and R 13 is divalent alkyl radical of 2-5 carbons. 6 23. A compound of Claim 22 where there is no optional R 2 R 3 is 7 H, A is (CH 2 )q and q is 0, B is COOH or a pharmaceutically acceptable 8 salt thereof, COOR., or CONRRR 0 9 24. A compound of Claim 23 where X, is S.
25. A compound of Claim 24 where R 4 is 4-methylphenyl. 11 26. A compound of Claim 25 where the phenyl ring is 1,4 (para) 12 substituted by the A-B and tricyclic groups, and where B is COOH or a 13 pharmaceutically acceptable salt thereof, or COOR, where R8 is methyl 14 or ethyl.
27. A compound of Claim 24 where R 4 is 5-methyl(2-thienyl). 16 28. A compound of Claim 27 where the phenyl ring is 1,4 (para) 17 substituted by the A-B and tricyclic groups, and where B is COOH or a is pharmaceutically acceptable salt thereof, or COOR, where R, is methyl 19 or ethyl.
29. A compound of Claim 23 where X 1 is O. 21 30. A compound of Claim 29 where R 4 is 4-methylphenyl. 22 31 A compound of Claim 30 where the phenyl ring is 1,4 (para) 23 substituted by the A-B and tricyclic groups, and where B is COOH or a 24 pharmaceutically acceptable salt thereof, or COOR 8 where R, is methyl or ethyl. 26 32 A compound of Claim 29 where R4 is 5-methyl(2-thienyl). 27 33. A compound of Claim 32 where the phenyl ring is 1,4 (para) 28 substituted by the A-B and tricyclic groups, and where B is COOH or a 29 pharmaceutically acceptable salt thereof, or COOR 8 where R 8 is methyl or ethyl.
34. A pharmaceutical formulation comprising a compound of formula 1 as defined in claim 1 or a pharmaceutically acceptable salt thereof in admixture with a pharmaceutically acceptable excipient, carrier or diluent. Use of a compound of formula 1 as defined in claim 1 or a pharmaceutically acceptable salt thereof in the preparation of a medicament.
36. Use of a compound of formula 1 as defined in claim 1 or a pharmaceutically acceptable salt thereof as a retinoid-like compound, a retinoid antagonist and/or a retinoid inverse agonist.
37. A method for the treatment, prophylaxis or amelioration of skin-related diseases, cancerous and pre-cancerous conditions, diseases of the eye, cardiovascular diseases, conditions and diseases associates with Human Papilloma Virus (HPV), inflammatory diseases and/or neurodegenerative diseases comprising the step of administering to a subject a therapeutically effective amount of a compound of formula 1 as defined in claim i 1 or a pharmaceutically acceptable salt thereof. 0*00
38. Compounds of formula 1 and pharmaceutically acceptable salts thereof, pharmaceutical formulations containing same, uses thereof, processes for their preparation and methods of treatment involving same substantially as herein described especially with reference to the examples. DATED this 6th day of October 2000 Allergan Sales, Inc. By its Patent Attorneys DAVIES COLLISON CAVE
AU56929/98A 1996-12-12 1997-12-09 Aryl or heteroaryl substituted 3,4-dihydroanthracene and aryl or heteroaryl substituted benzo{1,2-g}-chrom-3-ene, benzo{1,2-g}-thiochrom-3-ene and benzo{1,2-g}-1,2-dihydroquinoline derivatives having retinoid antagonist or retinoid inverse agonist type biological activity Ceased AU728051B2 (en)
US08/764466 1996-12-12
US08/764,466 US5728846A (en) 1996-12-12 1996-12-12 Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives
PCT/US1997/022581 WO1998025875A1 (en) 1996-12-12 1997-12-09 ARYL OR HETEROARYL SUBSTITUTED 3,4-DIHYDROANTHRACENE AND ARYL OR HETEROARYL SUBSTITUTED BENZO[1,2-g]-CHROM-3-ENE, BENZO[1,2-g]-THIOCHROM-3-ENE AND BENZO[1,2-g]-1,2-DIHYDROQUINOLINE DERIVATIVES HAVING RETINOID ANTAGONIST OR RETINOID INVERSE AGONIST TYPE BIOLOGICAL ACTIVITY
AU5692998A AU5692998A (en) 1998-07-03
AU728051B2 true AU728051B2 (en) 2001-01-04
AU56929/98A Ceased AU728051B2 (en) 1996-12-12 1997-12-09 Aryl or heteroaryl substituted 3,4-dihydroanthracene and aryl or heteroaryl substituted benzo{1,2-g}-chrom-3-ene, benzo{1,2-g}-thiochrom-3-ene and benzo{1,2-g}-1,2-dihydroquinoline derivatives having retinoid antagonist or retinoid inverse agonist type biological activity
AT (1) AT215925T (en)
AU (1) AU728051B2 (en)
BR (1) BR9714023B1 (en)
IL (1) IL129925D0 (en)
NO (1) NO312586B1 (en)
NZ (1) NZ335651A (en)
WO2000061233A2 (en) * 1999-04-14 2000-10-19 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease involving a specific rar-gamma agonist
AU9081601A (en) 2000-09-13 2002-03-26 Squibb Bristol Myers Co Retinoic acid receptor antagonists as promoters of angiogenesis
DK0638071T3 (en) * 1992-12-28 1997-10-27 Eisai Co Ltd Heterocyclic carboxylic acid derivatives which bind to retenoidreceptorer (RAR)
1996-12-12 US US08/764,466 patent/US5728846A/en not_active Expired - Fee Related
1997-12-09 JP JP52690498A patent/JP2001505914A/en active Pending
1997-12-09 CN CN97180511A patent/CN1102573C/en not_active IP Right Cessation
1997-12-09 EP EP97953123A patent/EP0948478B1/en not_active Expired - Lifetime
1997-12-09 BR BRPI9714023-6A patent/BR9714023B1/en not_active IP Right Cessation
1997-12-09 AU AU56929/98A patent/AU728051B2/en not_active Ceased
1997-12-09 IL IL12992597A patent/IL129925D0/en unknown
1997-12-09 WO PCT/US1997/022581 patent/WO1998025875A1/en not_active Application Discontinuation
1997-12-09 ES ES97953123T patent/ES2176813T3/en not_active Expired - Lifetime
1997-12-09 DE DE69711923A patent/DE69711923D1/en not_active Expired - Fee Related
1997-12-09 CA CA002274838A patent/CA2274838A1/en not_active Abandoned
1997-12-09 NZ NZ335651A patent/NZ335651A/en unknown
1997-12-09 AT AT97953123T patent/AT215925T/en not_active IP Right Cessation
1997-12-09 KR KR1019997005101A patent/KR20000069375A/en not_active Application Discontinuation
1997-12-09 DE DE69711923T patent/DE69711923T2/en not_active Expired - Lifetime
1998-02-25 US US09/030,350 patent/US6087505A/en not_active Expired - Fee Related
1999-06-11 NO NO19992871A patent/NO312586B1/en not_active IP Right Cessation
2000-01-13 US US09/482,700 patent/US6538149B1/en not_active Expired - Fee Related
2003-01-02 US US10/336,344 patent/US7166726B2/en not_active Expired - Fee Related
2006-12-21 US US11/643,754 patent/US20070265449A1/en not_active Abandoned
US20070265449A1 (en) 2007-11-15
DE69711923T2 (en) 2002-10-31
WO1998025875A1 (en) 1998-06-18
DE69711923D1 (en) 2002-05-16
ES2176813T3 (en) 2002-12-01
BR9714023B1 (en) 2009-12-01
AT215925T (en) 2002-04-15
BR9714023A (en) 2000-05-09
IL129925D0 (en) 2000-02-29
JP2001505914A (en) 2001-05-08
CA2274838A1 (en) 1998-06-18
US5728846A (en) 1998-03-17
US7166726B2 (en) 2007-01-23
EP0948478B1 (en) 2002-04-10
NO992871D0 (en) 1999-06-11
NO992871L (en) 1999-08-11
NZ335651A (en) 2000-09-29
EP0948478A1 (en) 1999-10-13
US20030130515A1 (en) 2003-07-10
US6538149B1 (en) 2003-03-25
AU5692998A (en) 1998-07-03
US6087505A (en) 2000-07-11
CN1239941A (en) 1999-12-29
KR20000069375A (en) 2000-11-25
NO312586B1 (en) 2002-06-03
CN1102573C (en) 2003-03-05
AU726450B2 (en) 2000-11-09 Dimer-selective RXR modulators and methods for their use
AU680992B2 (en) 1997-08-14 (4-(1,2-epoxycyclohexanyl) but-3-EN-1-ynyl) aromatic and heteroaromatic acids and derivatives having retinoid-like biological activity
CA2133587C (en) 2008-11-18 Compounds having selectivity for retinoid x receptors
AU715624B2 (en) 2000-02-03 Substituted aryl or heteroarylamides having retinoid-like biological activity
US5847160A (en) 1998-12-08 Acetylenes disubstituted with 2-tetrahydropyranoxy-aryl and aryl of heteroaryl groups having retinoid-like biological activity
EP0580738B1 (en) 1997-05-21 7-chromanyl esters of phenols and benzoic acids having retinoid-like activity
Owner name: ALLERGAN, INC
Free format text: FORMER OWNER WAS: ALLERGAN SALES, INC.